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Type 1 diabetes (T1D) is a chronic condition caused by the complete destruction of insulin 
producing pancreatic β-cells. Increased oxidative stress and impaired antioxidant capacity are 
associated with the development of diabetic complications such as diabetic nephropathy. 
Metformin, a drug commonly used in the treatment of type 2 diabetes, has been suggested to 
have antioxidant capacity. We hypothesise that metformin, when used as an adjunct to insulin 
in T1D may help prevent the development of diabetic nephropathy by decreasing oxidative 
stress.  
Sprague-Dawley rats (230-250g) were divided into 5 groups, (Group A: untreated controls, 
B: diabetic control, C: T1D + insulin (4U/kg twice daily), D: T1D + metformin (250mg/kg 
via oral gavage), E: T1D + metformin + insulin). Diabetes was induced in groups B-E by 
intraperitoneal streptozotocin injection at a dose of 65mg/kg body weight and diabetes was 
confirmed 48 hours later. Glucose tolerance test, serum and urinary electrolytes (K+,Cl-
,Na+), creatinine, urea, superoxide dismutase activity, glutathione concentration and  
malondialdehyde concentration were analysed. 
Metformin alone did not improve glucose intolerance. Both the diabetic control group as well 
as the group treated with metformin alone experienced hyperglycemia, polydipsia, polyuria, 
weight loss and impaired glucose tolerance. However, when metformin was added to insulin 
there was a significant increase in electrolyte excretion and also greatly improved creatinine 
clearance when compared to the diabetic control group. Metformin with insulin further 
reduced superoxide dismutase activity compared to the diabetic control, increased glutathione 
concentration as well as reduced malondialdehyde concentrations in both plasma and renal 
tissue. In conclusion, metformin has positive additive effects on oxidative stress and renal 






1.1 Diabetes epidemiology  
Diabetes mellitus exists in two forms, type 1 and type 2, which are both characterised by 
chronic hyperglycaemia. Diabetes occurs when the body either cannot produce insulin or is 
unable to utilise insulin efficiently or both [1, 2]. In type 1 diabetes hyperglycaemia occurs 
due to complete destruction of the β- cells in the pancreatic islets of Langerhans. This is 
usually attributed to autoimmune processes whereby the immune system destroys the beta 
cells [2, 3]. As a result of the destruction of these cells, there is an absolute deficiency of 
insulin, leading to complete reliance on exogenous insulin administration for survival [3]. In 
type 2 diabetes however, insulin effects are diminished due to insulin resistance. This 
eventually leads to compensatory deficiency in insulin secretion resulting in elevated blood 
glucose levels [2, 4]. Insulin resistance develops due to alterations in the insulin cell receptor 
[4]. Factors contributing to the development of type 2 diabetes include: obesity, ethnicity, 
poor diet and physical inactivity [2]. 
Rarely, diabetes may be caused by genetic defects, diseases of the pancreas, viral infections 
and drug/chemical ingestion. Although virus-induced diabetes is rare, congenital rubella, 
coxsackievirus B, cytomegalovirus, adenovirus and mumps have all been implicated in 
causing the development of diabetes [4]. Diabetes may also be caused by ingestion of toxins 
or drugs. Large doses of exogenous steroids such as glucocorticoids can cause impaired 
insulin action and pancreatitis [4]. Toxins such as pentamidine can cause permanent β-cell 
destruction, whereas interferon-α treatment has been associated with islet-cell antibodies 
resulting in insulin deficiency [4]. 
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It is estimated that 8.2% of the global population is diagnosed with some form of diabetes [2]. 
According to the International Diabetes Federation, 19.8 million Africans had diabetes in 
2013 with this figure expected to triple to 66 million by the year 2035 [2]. While South 
Africa has a 8.27% prevalence rate of diabetes [2]. It was approximated that by the year 
2013, 29.7 million Africans were living with impaired glucose tolerance or type 2 diabetes, 
with 8.3% national prevalence in South Africa [2]. Africa as a whole experiences 
approximately 6400 new cases of type 1 diabetes annually. South Africa has an incidence rate 
of 0.8 per 100 000 children between 0-14 years old having type 1 diabetes, suggesting that 
there is a rapid increase in diabetes cases every year [2]. The reason for the steady increase in 
diabetes is still not entirely clear, although, environmental factors, diet and viral infections 
are hypothesised to play a role [2].  
 
Added to the diabetes burden are associated microvascular and macrovascular complications 
such as nephropathy, retinopathy and cardiovascular disease which result in increased 
mortality each year. The disease burden of diabetes in Africa is also confounded by the 
socioeconomic status where a large proportion of diabetic patients go undiagnosed. Thus the 
true impact of the disease could be much larger than the current statistics suggest [5]. With a 
high rate of unemployment in South Africa, confirmed cases of diabetes rely on public health 
funding which is severely constrained by the HIV/TB disease burden [6].  Treatment costs an 
average diabetic South African $935 annually in diabetes-related expenditure [2]. However, 
patients have no alternatives as poorly managed diabetes leads to increased morbidity and 
mortality. These complications, if not actively taken care of, may be debilitating and life 





The primary aim of treatment for both type 1 diabetes (T1D) and type 2 diabetes (T2D) is 
optimized glycaemic control which mitigates the development of diabetes complications [7]. 
T1D is treated using insulin therapy. As insulin is a polypeptide it is orally degraded and 
therefore is administered normally through subcutaneous injections. However, novel drug 
delivery systems are currently exploring transdermal and inhaled forms of the drug [8]. 
Glycaemic control is dependent on patient blood-glucose monitoring and maintaining 
normoglycemic levels whilst preventing large fluctuations in blood-glucose levels [8]. This 
has become easier to achieve with the creation of continuous subcutaneous infusion and long-
acting insulins [8]. However, these treatments are expensive and are beyond the reach of most 
diabetic patients. T2D is treated with a combination of lifestyle modifications and drug 
therapy. Lifestyle modifications include dietary changes, increased exercise and weight 
control. There are three major groups of oral hypoglycaemic agents used in T2D, these 
include biguanides, sulphonylureas and thialzolidirediones [1, 8]. Biguanides such as 
metformin reduce hepatic gluconeogenesis, increase fatty acid oxidation and act as insulin 
sensitizers. Sulphonylureas are insulin secretagogues as they promote insulin release from the 
pancreas by blocking ATP-sensitive K
+
 channels causing a depolarization, a Ca
+2
 influx and 
ultimately  insulin release [1, 8]. Thialzolidinediones also act as insulin sensitizers by 
activating peroxisome proliferator-activated receptors (PPARs) and improve insulin 
sensitivity in the peripheral tissues [1, 8]. Emerging treatments include glucagon-like peptide 
1 (GLP-1) agonists, acarbose and sodium-glucose transporter 2 (SGLT-2) inhibitors. GLP-1 
agonists are an incretin therapy. GLP-1 receptor agonists enhance insulin secretion and 
synthesis as well as decrease postprandial glucagon secretion whilst slowing gastric emptying 
and prolonging satiety [9, 10]. Acarbose prevents the breakdown of complex carbohydrates to 
monosaccharides whilst reducing postprandial hyperglycemia [10]. SGLT-2 inhibitors 
increase urinary glucose excretion whilst inhibiting glucose reabsorption [10].      
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1.2 Diabetes Complications  
Diabetic complications are largely categorised as microvascular and macrovascular. 
Microvascular complications include retinopathy, nephropathy and neuropathy while the 
major macrovascular complications include atherosclerosis leading to accelerated 
cardiovascular disease, myocardial infarction and cerebrovascular diseases such as strokes [3, 
11].  Microvascular complications involve damage to small blood vessels in the body 
whereas macrovascular complications involve damage to large vessels. [8] 
 
Diabetic retinopathy is associated with damage to retinal vasculature which causes changes in 
vascular permeability and neovascularisation. This can lead to blindness and visual 
impairment in diabetic patients [3, 8]. Prolonged hyperglycemia causes changes in the blood-
retina barrier [3]. Treatment includes blood pressure and glycaemic control, coupled with 
invasive procedures such as steroid injections and laser treatment in severe cases [3] 
 
Neuropathy, or nerve damage, is one of the most common long-term complications 
experienced in diabetes [8]. Diabetic neuropathy involves both the somatic and autonomic 
peripheral nervous systems and symptoms include loss of sensation, dysesthesia, pain, 
weakness and impaired wound healing [3, 8]. Neuronal blood flow is compromised by 
capillary basement membrane thickening causing reduced oxygen supply. Treatment focuses 
on blood glucose control and pain management[3].  
 
Cardiovascular disease is the leading cause of mortality in T1D [12]. Common cardiovascular 
disorders in diabetes include hypertension, atherosclerosis, endothelial dysfunction, increased 
levels of apoptosis in myocytes and an increased risk of myocardial infarction, heart failure 
and stroke [13]. Patients are managed with blood-pressure lowering agents such as 
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Angiotensin Converting Enzyme inhibitors (ACE-inhibitors), lipid lowering drugs such as 
statins and antiplatelet agents such as low-dose aspirin, all whilst maintaining strict 
glycaemic control using regular anti-diabetic agents [3] 
 
 Diabetic nephropathy is one of the most common co-morbidities found in diabetes and 
contributes significantly to diabetes-related deaths. Diabetic nephropathy encompasses the 
following functional changes: glomerular hyperfiltration, epithelial hypertrophy, 
microalbuminuria, glomerular basement membrane thickening and proteinuria [14, 15]. Up to 
40% of diabetic patients will develop some form of diabetic nephropathy despite adequate 
glycaemic control [15]. Current treatment regimens include intensive glycaemic control and 
the use of ACE-inhibitors. Oxidative stress and prolonged hyperglycemia are the biggest 
driving forces behind the progression of diabetic nephropathy and other diabetic 
complications. Therefore, emphasis should be placed on improving the management of these 
complications as this could decrease the mortality rate associated with diabetes.   
 
1.3 Impact of hyperglycemia and oxidative stress on diabetic complications 
 
Hyperglycaemia plays an integral role in the development of diabetic complications. The 
duration and degree of hyperglycaemia increases the prevalence of complications [16]. It is 
thought that diabetes complications arise as a result of prolonged periods of hyperglycaemia 
as well as partially through an increase in oxidative stress and impaired antioxidant capacity 
[17, 18]. Hyperglycemia causes tissue damage through a number of mechanisms, all of which 
are as a result of mitochondrial overproduction of Reactive Oxygen Species (ROS) [19]. 
Hyperglycemia has also been shown to decrease the body’s total antioxidant capacity and 
increase oxidative stress [20]. However, even with well controlled glucose levels, diabetic 
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patients still develop complications such as nephropathy, retinopathy and cardiovascular 
disease. This has implicated oxidative stress and antioxidant mechanisms in the development 
of diabetes complications [21]. The increase in ROS such as superoxide (O2
•- 
) with reduced 
antioxidant capability is a common  phenomenon in diabetes [18]. Superoxide is the initial 
free radical produced in the mitochondria and activates numerous pathways involved in the 
pathogenesis of diabetes complications [19]. 
 
Hyperglycemia produces oxidative stress and tissue damage through at least 4 recognised 
mechanisms; increased activity of the polyol pathway, an increase in formation of advance 
glycated end products (AGEs), increased activation of protein kinase C (PKC) isoforms and 
overactivity of the hexosamine pathway [19]. In the polyol pathway, excess glucose is 
converted to sorbitol through activation by aldose reductase which requires Nicotinamide 
Adenine Dinucleotide Phosphate (NADPH) a major co-factor required to regenerate reduced 
glutathione (GSH) from its oxidised form (GSSG) [19, 21]. Glutathione is an important 
scavenger of ROS and its decrease could exacerbate intracellular oxidative stress [19, 21]. In 
hyperglycaemic conditions, NADPH is used by aldose reductase in the polyol pathway of 
oxidative stress rather than being used by glutathione in the antioxidant pathway; therefore 
oxidative stress is preferred and the cell is unable to withstand the oxidative stress insult as 




Figure 1: Glutathione depletion due to aldose reductase utilisation of NADPH in polyol 
pathway [22] .  
 
As a result of increased superoxide production by the mitochondrial Electron Transport Chain 
(ETC), oxidative stress is increased [19]. Under normal conditions electrons are passed 
through complexes I-IV and eventually to molecular oxygen which it reduces to water, 
limiting oxidative phosphorylation (Fig. 2) [19]. However, in diabetic conditions with 
hyperglycemia present there is a flux of electron donors (NADH and FADH2) to the 
mitochondrial ETC [21, 23]. This causes the voltage gradient of the mitochondrial membrane 
to reach critical threshold causing electrons to pile up to coenzyme Q and leak out at 
complexes I and III [19, 21, 23]. As they are released from the transport chain, the electrons 
bind molecular oxygen and generate superoxide ions [19, 21, 24]. Under normal conditions 
electrons reduce molecular oxygen to water; however, under hyperglycaemic conditions 
oxygen is partially reduced and superoxide is formed instead [21]. Superoxide leads to the 
inhibition of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which ultimately 
increases the flux into the 4 pathways of hyperglycaemic damage [15, 19, 21]. Reduced 
activity of GAPDH causes a switch to the polyol pathway, activates PKC, increases AGE 
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formation and upregulates the hexosamine pathway [21]. For example, inhibition of GAPDH 
increases intracellular glucose levels which leads to increased activity of the polyol pathway 
[15, 19]. Similarly when there is reduced GAPDH activity there is an increase in 
diacylglycerol (DAG) which leads to activation of the PKC pathway [15, 19, 21].    
 
Figure 2: ROS production in electron transport chain [19] 
 
Superoxide dismutase (SOD) is another powerful antioxidant that is capable of combating 
oxidative stress [3]. SOD converts O2
•- 
 into hydrogen peroxide which is then converted to 
H2O and O2 by catalase [18, 19]. Hence, SOD activity provides a marker for the presence of 
oxidative stress.  It exists in two forms, Cu/Zn-SOD which is found in the cells cytosol and 
Mn-SOD which is found in the mitochondria [18]. Hyperglycemia has been shown to 
decrease the concentrations of SOD [20]. It is therefore thought that SOD reduction may 
perhaps play a role in the development of nephropathy and other diabetes complications [18]. 
Under hyperglycaemic conditions, ROS causes SOD activity to increase; however, SOD 
becomes depleted and antioxidant defences compromised, this leads to worsening of diabetes 
complications such as diabetic nephropathy.   
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1.4 Diabetic nephropathy 
Diabetic nephropathy is a common complication both in T1D and T2D [25]. It is estimated 
that between 20-40% of diabetic patients will develop diabetic nephropathy in their lifetime 
regardless of glycaemic control [15]. Diabetic nephropathy is a progressive and irreversible 
renal disease and it is now the leading cause of end-stage renal disease worldwide [25-27]. It 
is characterised by morphological changes such as extra cellular matrix expansion and 
thickening of the glomerular basement membrane which lead to kidney damage  [25, 27].  
 
Progression of diabetic nephropathy occurs in 5 steps [26]. The first stage, hyperfiltration, is 
usually seen 3-5 years after the onset of type 1 diabetes and is characterised by increased 
kidney size, enlarged glomeruli and increased glomerular filtration rate [15, 26]. Stage 2 is 
silent where glomerular filtration rate returns to normal and there is minimal albumin 
excretion, it may last 2-5 years [15, 26]. Stage 3 occurs 6-15 years after diagnosis and is 
associated with basement membrane thickening and extra cellular matrix expansion. 
Increases in blood pressure may be apparent and glomerular filtration rate (GFR) is either 
normal or slightly decreased [15, 26]. Stage 4 is overt nephropathy and occurs 10-25 years 
after diagnosis with type 1 diabetes with visible structural changes, increasing hypertension, 
and a rapidly falling GFR [15, 26, 28]. At this stage GFR is likely to decrease on average at a 
rate of 12-15ml/min/year and macroalbuminuria (urinary albumin of between 20-200 
mcg/min) may be present [15, 26]. End stage kidney disease is associated with severe 
hypertension, glomeruloscelrosis and very low GFR and usually occurs 20-30 years after 
initial diagnosis [15, 26]. 
 
Pathogenesis of diabetic nephropathy is not fully understood but 3 major pathways are 
thought to be involved [25, 29]. Oxidative stress, specifically the formation of AGEs and the 
10 
 
activation of the PKC and polyol pathways, have been proposed to be contributing factors in 
the development and progression of diabetic nephropathy [15, 27]. Hyperglycemia and 
increased oxidative stress are the two prominent driving forces associated with the 
progression of diabetic nephropathy [15]. 
 
High glucose concentrations in hyperglycaemic states irreversibly binds with amino acids to 
form glycosylated products (AGEs) which cause severe damage to the kidney [15]. The 
AGEs cross-link with collagen and increase the matrix proteins in the glomerular cells. This 
contributes to the formation of structural changes associated with diabetic nephropathy by 
increasing basement membrane thickening and exacerbating glomerulosclerosis [15]. AGEs 
further exacerbate kidney damage by causing increased production of ROS leading to 
increased oxidative stress [15].  
 
AGEs induce oxidative stress which activates the PKC pathway which plays an important 
role in the pathogenesis of diabetic nephropathy [25, 27]. Studies suggest that PKC-α 
activation is involved in the development of albuminuria and PKC-β activation is involved in 
mesengial expansion, glomerular basement membrane thickening and renal hypertrophy [15]. 
There is also a link between the polyol pathway and the pathogenesis of diabetic nephropathy 
where excess glucose is converted to sorbitol through activation by aldose reductase [21]. 
Studies have shown that when aldose reductase inhibitors are administered, there is decreased 
urinary albumin excretion suggesting a direct role of aldose reductase in the development of 
diabetic nephropathy [15].   
 
In diabetic patients, oxidative stress can cause direct damage to the glomerular cells and 
effect tubule-interstitial structure and function, thus leading to diabetic nephropathy [30]. 
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Patients with diabetic nephropathy exhibit reduced numbers of cells in the kidney which form 
part of the Bowmans capsule, podocytes. This alters glomerular permeability leading to 
proteinuria prior to full blown diabetic nephropathy [15, 31, 32]. Podocytopenia is used as a 
predictor of clinical diabetic nephropathy [29].  Hyperglycemia enhances ROS production in 
podocytes which concomitantly with NADPH oxidase activation plays a key role in podocyte 
apoptosis [14, 31]. NADPH oxidase inhibition has been shown to significantly decrease 
urinary albumin excretion and podocyte depletion [14].  
 
A reduction in renal function may also lead to retention of electrolytes and toxins in the body 
[33]. It is not uncommon to find hypernatremia and hyperkalemia in the presence of kidney 
failure [33, 34]. This could potentially lead to additional morbidities such as cardiac 
dysrhythmias, increased blood pressure and other cardiovascular problems [33, 34].  
 
1.5 Current treatment of diabetic nephropathy  
Currently, diabetic nephropathy is progressive and irreversible; hence, treatment focus is on 
delaying disease progression and not on remission [35]. Current strategies to prevent the 
progression of diabetic nephropathy are multifactorial. These include lifestyle changes, 
intensive glycaemic control and blood pressure control [36]. Hyperglycemia, hypertension 
and lifestyle factors such as smoking cause an increase in oxidative stress, inflammation and 
renal injury [35]. According to the Diabetes Control and Complications Trial (DCCT) 
intensive glycaemic control (HbA1c of ≤7%) can reduce the risk of new onset 
microalbuminuria as well as delay the progression of nephropathy [35, 37].  
 
Hypertension is viewed as a high risk factor contributing to both the onset as well as the 
progression of diabetic nephropathy, therefore blood pressure control is important in delaying 
12 
 
or preventing the development of diabetic nephropathy [36, 38]. Currently type 1 diabetes 
patients are treated with angiotensin converting enzyme inhibitors (ACE inhibitors) to control 
hypertension. The renin angiotensin system (RAS) plays an important role in the 
development of micro- and macrovascular complications such as diabetic nephropathy  [39]. 
Diabetes and hyperglycemia leads to increased RAS activation in tissue and elevated 
angiotensin II (Ang II) concentrations [40]. Under normal non-diabetic conditions the RAS is 
stimulated due to hypotension, salt depletion or central nervous system excitation [39]. 
Prorenin is produced in the juxtaglomerular cells and is cleaved into renin, renin then 
enzymatically acts on angiotensin (AGT) to form angiotensin I (Ang I), which is catabolised 
by angiotensin-converting enzyme (ACE) to form the biologically active Ang II [40, 41]. Via 
the angiotensin type 1 receptor (AT1), Ang II causes vasoconstriction, increased 
intraglomerular pressure, renal tubule sodium reabsorption, inhibition of renin release, 
aldosterone secretion and thirst [40]. Aldosterone seceretion is the main cause of sodium and 
water retention [39].  Ang II has vasoconstrictive effects and causes constriction in the 
glomerular mesangial cells causing an increase in GFR and leading to kidney damage [41]. 
ACE inhibitors act on ACE and prevent the conversion of angiotensin I to angiotensin II. 
ACE inhibitors, through inhibition of the RAS cause relaxation of efferent arterioles, 
reduction in intraglomerular pressure and proteinuria, therefore leading to delayed 
progression to End Stage Renal Disease (ESRD) [39]. ACE inhibitor treatment has been 
shown to prevent an increase in albumin excretion and delay the rate of decline of glomerular 
filtration rate (GFR) [15, 35]. However, ACE inhibitor treatment is accompanied by its own 
short-comings and side effects such as the development of a dry cough which is common 
[39]. ACE inhibitor treatment only slows the progression of diabetic nephropathy and doesn’t 




A salt restriction diet is also recommended as it is important for blood pressure control and 
hence, the progression of diabetic nephropathy [35]. Some newer therapies that aim to target 
ROS directly have been tested yet none has been implemented in the current treatment 
regimes as clinical trials are still ongoing [35]. Some novel treatments such as aldose 
reductase targets and NOX-inhibitors are still under review [35]. In recent years it has also 
been suggested that metformin may possess antioxidant properties and could help prevent or 
delay the onset of diabetic complications such as diabetic nephropathy and cardiovascular 
disease.  
 
1.6 Glucose Metabolism 
Insulin is the gold standard in treatment for type 1 diabetes. The insulin receptor is 
heterotetrameric and consists of 2 α subunits and 2 β subunits which are linked by disulfide 
bonds [8, 42]. The extracellular α-subunits bind insulin whilst the β-subunits exist in the 
transmembrane and possess tyrosine kinase activity [43]. Insulin binding to the α subunit 
causes transphosphorylation of the β-subunits which leads to an increase in tyrosine kinase 
activity [42, 43].  Insulin stimulates a decrease in blood glucose concentration by facilitating 
glucose uptake into the cell by stimulating an increased rate in glucose transporter protein 
(GLUT-4) translocation from intracellular stores to the plasma membrane in fat and muscle 
cells [42]. The rate of glucose transport into the cell is dependent on the concentration of 
GLUT-4 transporters at the cell surface and for how long the concentration is maintained 
[43]. Insulin increases the rate of translocation of GLUT-4 to the plasma membrane thereby 
allowing for increased glucose uptake. Following insulin binding, GLUT-4 vesicles move 
along microtubule tracks before docking and fusing with the plasma membrane allowing for 
extracellular exposure [42, 43]. Once at the plasma membrane, circulating glucose then 
passes down a concentration gradient and is diffused into the cell. 
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Glucose inside the cell is then converted eventually to glycogen and stored after the process 








Figure 3: Glucose metabolism pathway [44] 
 In the presence of insulin, glycogen synthesis is increased while glycogen breakdown is 
inhibited. Although insulin is not required for glucose uptake by the liver, it stimulates 
glycogen synthesis and blocks glycogenolysis and gluconeogenesis [42]. Insulin also 
stimulates the expression of enzymes which favour glycolysis while inhibiting the expression 
of enzymes which favour gluconeogenesis by stimulating and inhibiting the gene expression 
which encode for these hepatic enzymes [42]. Insulin activates glycogen synthase by 
inhibiting kinases such as PKA and protein phosphatase, which downstram decreases the rate 
of phosphorylation of glycogen synthase, therefore increasing glycogen activity.  Circulating 






Metformin is a popular biguanide drug, commonly used as a first line therapy  in the 
treatment of type 2 diabetes [14]. Metformin is a relatively safe drug. Unlike other glucose 
lowering agents it very rarely causes hypoglycaemic episodes. It is a well-tolerated drug, with 
the most common side-effect being gastrointestinal disturbances. Metformin helps reduce 
blood glucose levels and is referred to as an insulin sensitizer as it increases the effects of 
insulin [32]. The effects of insulin become more pronounced due to increased insulin 
sensitivity and is accompanied by a reduction of the amount of insulin required to produce 
normoglycaemia [45]. Metformin’s effects are mediated by its suppression of hepatic 
gluconeogenesis, decreased fatty acid oxidation and increased peripheral insulin sensitivity, 
leading to improved glucose uptake in the skeletal muscle and adipocytes [16, 46, 47].  
 
 Even though metformin has been in use for the last 50 years, its precise mechanism of action 
has yet to be elucidated [45, 48]. The liver is the main site of action of metformin [48]. When 
metformin is administered orally, its highest concentrations can be found in the liver [45, 48]. 
This is due to the high levels of organic cation transporter 1 (OCT1) expressed in 
hepatocytes. Metformin is a polar molecule and requires the membrane transporter OCT1 in 
order to gain entrance into the cell. Once inside the liver, metformin promotes glucose 
uptake, a decrease in gluconeogenesis, and an increase in glycolysis and glycogen synthesis 
[48]. It is thought that metformin may work in several ways in order to decrease blood 
glucose levels. Metformin increases plasma levels of glucagon-like peptide (GLP-1). GLP-1 
increases the secretion of insulin and reduces the secretion of glucagon in the presence of 
glucose [48]. Metformin enhances insulin activity by increasing the translocation of glucose 
transporter GLUT-2 and GLUT-1 to the plasma membrane within hepatocytes. This results in 
an increase in the amount of glucose taken up by the liver and consequently increases 
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glycogen synthesis whilst decreasing gluconeogenesis [48]. Metformin also increases insulin 
receptor expression [48]. Studies have shown that when metformin is added to insulin therapy 
in type 1 diabetics there is usually a reduction in the insulin dose required [49, 50]. This is 
due to metformin’s insulin enhancing effects. Less insulin is required in order to achieve 
normal glycaemic levels. Metformin’s major mechanism of action is it’s activation of 5’- 
AMP-activated protein kinase (AMPK) [48, 51]. 
 
Once inside the hepatocyte cytosol, metformin acts predominantly in the mitochondria. 
Although its mechanism is not entirely known, it is thought that through a secondary side 
effect metformin  inhibits complex 1 of the mitochondrial ETC [48]. Among other things this 
blocks the reverse electron flow at complex 1, common under diabetic conditions, and 
therefore inhibits mitochondrial ROS production [45]. Metformin has been shown to increase 
MnSOD levels compared to Cu/ZnSOD. The reason for this is because metformin acts 
predominantly in the mitochondria and not in the cytosol. MnSOD is found in the 
mitochondria whereas Cu/ZnSOD is found in the cytosol. Metformin therefore potentially 
reduces ROS production and increases antioxidant potential [52].       
 
Other studies have suggested that metformin derives the majority of its actions through either 
direct or indirect activation of AMPK [45, 48, 51]. AMPK is a known master energy sensor, 
that restores energy balance within the cell [53]. Once activated it switches the cell from an 
anabolic state to a catabolic state, arresting adenosine triphosphate (ATP)-consuming 
pathways in favour of ATP-generating pathways. It does this by enhancing catabolic 
pathways which increase ATP levels such as glycolysis and fatty acid oxidation while 
inhibiting anabolic pathways that consume ATP [54, 55]. Glycolysis and fatty acid oxidation 
are the only ATP producing pathways under anaerobic conditions. Under these conditions 
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glucose, fat and protein synthesis are inhibited [45]. AMPK effects this by phosphorylating 2 
protein kinase β (Akt) substrates [55]. Activated AMPK inhibits triglyceride and protein 
synthesis as well as glucose production in the liver [56, 57].  
  
As a result of metformin transiently inhibiting the mitochondrial electron transport chain, 
there is a decrease in energy charge and this causes a decrease in ATP production within the 
cell [45, 48]. The inhibition of complex 1 causes a reduction in NADH oxidation which leads 
to a lowering of the proton gradient and reduces the proton motive force that is required for 
ATP production [45, 48]. The decrease in ATP causes a concomitant rise in adenosine 
monophosphate (AMP) concentration [51]. The increase in AMP is thought to drive two 
major pathways in metformin’s ability to decrease gluconeogenesis. Firstly, elevated AMP 
inhibits adenylate cyclase which is an enzyme responsible for the conversion of ATP to 
cAMP. Reduced cAMP has been implicated in a reduction in gluconeogenesis [51]. 
Suppression of adenylate cyclase in turn down-regulates protein kinase A (PKA) which is a 
downstream activator of gluconeogenic gene expression [51]. Secondly, an increase in AMP 
causes an increase in the ratio of AMP:ATP  which causes an activation of AMPK [45, 48, 
51]. AMPK promotes glucose uptake in the muscles and an inhibition of lipid synthesis in the 
liver (Fig. 4) [48, 51]. This therefore provides evidence that metformin has an indirect role in 

















Figure 4: Metformin mechanism of action [48] 
 
1.8 Metformin use in type 1 diabetes 
There are currently no indications for metformin to be prescribed in T1D. Few studies have 
looked at the use of metformin in T1D. Of these studies the majority found a significant 
reduction in the amount of insulin used by patients on a daily basis but found no significant 
reduction in HbA1c levels [49, 50, 58, 59]. The proposed explanation for this was that 
patients titrated down their insulin dose in order to maintain their normal glucose levels and 
to avoid becoming hypoglycemic since metformin increases insulin sensitivity in T1D [59, 
60].  
 
It has been well established that metformin treatment in T2D reduces cardiovascular risk 
factors [60]. Metformin, through its action on eNOS, activates AMPK and reduces vascular 
inflammation, protects the endothelium from oxidative stress and reduces myocardial injury 
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after ischemia. By producing glycolytic ATP during periods of cardiac ischemia, AMPK is 
said to have a cardioprotective role [55]. Through these actions metformin has been shown to 
decrease the incidence of cardiovascular disease, improve mitochondrial oxygen consumption 
and improve endothelial function [61, 62]. Some studies have shown a reduction in total 
cholesterol while on metformin; however, this has not been significant in the majority of 
studies [49, 60].  
 
The inclusion of metformin with insulin in the treatment of T1D may in theory cause an 
increase in hypoglycaemic episodes, though the majority of studies found no significant 
increase in hypoglycaemic episodes [49]. However, this can easily be avoided through 
glucose monitoring and adjustment of insulin dosage.    
 
After a thorough literature review it was found that there have been no previous studies 
evaluating metformin effects on diabetic nephropathy in T1D.  
 
1.9 Metformin use in chronic kidney disease 
Although metformin is used as a first-line treatment of type 2 diabetes (T2D), there are 
concerns of its safety in patients with kidney disease.  This is because it is excreted almost 
exclusively via the renal system with a potential of causing lactic acidosis.  Lactic acidosis is 
a serious condition where arterial lactate levels are elevated and blood pH drops to below 
7.35 [63]. Another biguanide, metformin’s predecessor, phenformin was removed from the 
market due to a high incidence of drug induced lactic acidosis (LA) [64]. Though the risk of 
lactic acidosis on metformin has been shown to be relatively low, bigaunides have been 
shown to increase plasma lactate concentrations and concurrently decrease lactate 
metabolism [65]. Phenformin induces the conversion of glucose to lactate and impairs its own 
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renal excretion [66]. It causes lactic acidosis through pyruvate accumulation due to 
gluconeogenesis inhibition. Oxidation of fatty acids causes a depletion of NAD
+
 and 
increases NADH. Simultaneously, phenformin inhibition of oxidative phosphorylation 
impairs NAD
+
 generation from NADH which further increases the NADH/NAD
+
 ratio. A 
increase in this ratio inhibits pyruvate dehydrogenase and therefore inhibits pyruvate entry 
into the Krebs cycle [65]. This causes an accumulation of pyruvate which is then metabolised 
to lactate. Fatty acid metabolism which produces ketone bodies, cause further exacerbation of 
acidosis [65]. Biguanide-associated lactic acidosis has also been linked to their inhibition of 
complex 1 of the mitochondrial respiratory chain, where inhibition of mitochondrial oxidative 
phosphorylation is correlated with increased plasma lactate concentration [63]. 
 
Reports suggest that metformin has an incidence rate of LA 20 times less than phenformin 
[63]. Metformin has a wider therapeutic window compared to phenformin and requires higher 
blood concentrations of the drug to produce lactic acidosis [63]. Phenformin undergoes 
hepatic metabolism and is excreted renally whereas metformin is excreted unchanged by the 
kidneys [65-67]. Therapeutic doses of metformin causes almost no increase in blood lactate 
levels [63] Due to perceived risk of LA in renal impairment, most guidelines recommended 
that when glomerular filtration drops to <60 ml/min, metformin therapy should be 
discontinued [64]. However, this has recently been revised to discontinuation when GFR is 
<30 ml/min [64]. Studies have shown that there is no difference in the incidence of LA in 
diabetic patients taking metformin as opposed to those not on metformin [67]. Another study 
found no difference in the incidence of lactic acidosis between metformin and sulfonylureas 
[63].  
Metformin not only improves glycaemic control but also has cardioprotective properties and 
has been proposed to have renoprotective effects which could potentially delay the onset of 
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nephropathy [68]. Therefore, the benefits of metformin therapy could outweigh the risks, 
even in chronic kidney disease.  
 
1.10 Metformin use to prevent diabetic nephropathy 
Although the exact mechanism of action by which metformin could exert renoprotective 
effects is unknown, the ability of metformin to reduce ROS as well as prevent tubular cell 
injury may be the contributing factor [29, 32, 69]. Morales et al. (2010) showed that 
metformin can improve gentamycin induced nephrotoxicity and renal tubular injury [70]. 
Gentamycin is a common nephrotoxic antibiotic and causes necrosis of the proximal tubular 
cells, apoptosis and reduced levels of ATP in the renal tubular cells [70]. Metformin was 
shown to improve renal blood flow as well as prevent mitochondrion derived oxidative stress, 
possibly through its transient activity at complex-1 on the respiratory electron chain [70]. In 
the same study, it was shown that metformin has preconditioning effects by preventing the 
opening of the mitochondrial permeability pore (mPTP). Opening of the mPTP causes an 
influx of solutes and water, this causes the outer mitochondrial membrane to rupture and 
release the contents of the inter-membranous space into the cytosol [71]. Pro-apoptotic 
factors are released which lead to necrosis, apoptosis and cell death [71, 72].   
 
In a diabetic state metformin has been reported to have a protective effect on the renal tubules 
and podocytes [31, 32]. As with gentamycin induced toxicity, it is thought that ROS 
produced in the mitochondria may play a significant role in diabetic nephropathy [32]. Pro-
apoptotic factors which are released may cause cell damage, there is therefore merit in 
attempting to protect the mitochondria and prevent mitochondrial ROS production to prevent 
nephrotoxicity [32]. Based on these findings it is conceivable to suggest that metformin can 
attenuate diabetic nephropathy by decreasing ROS production and oxidative injury [32]. 
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Additionally metformin not only has protective effects but also has ameliorative properties, 
and is capable of reversing renal damage [32]. While ROS levels are elevated in a diabetic 
conditions, AMPK levels are reduced [73, 74] suggesting that hyperglycaemia decreases 
antioxidant capacity [17, 18]   
    
It has been shown in diabetic rats that podocyte density is decreased with increased 
albuminuria which is attenuated with metformin therapy suggesting a reversal of podocyte 
injury [32, 73]. It is hypothesised that metformin’s renoprotective effects could at least be 
partly due to its anti-oxidative activity[73].  The most likely mechanism of action for this 
would either be through metformin’s inhibition of complex 1 of the mitochondrial electron 
transport chain, and/or its activation of AMPK [31, 73].  
As metformin is a well-tolerated, safe drug which may possess positive antioxidant abilities, 
this study therefore seeks to investigate the merits of using metformin as an adjunctive 
therapy to insulin in the treatment of T1D in order to prevent or delay the occurrence of 












 1.11 Aim 
To investigate the effects of metformin on renal function and glucose tolerance in a type 1 
diabetes rat model.  
 
1.12 Objectives 
• To investigate metformin’s effects on glycaemic control and glucose tolerance in T1D 
• To investigate metformin’s effect on oxidative stress in plasma and renal tissue and its 

















CHAPTER TWO:  
MATERIALS AND METHODS  
 
 
 2.1 Chemical Reagents 
The following reagents were purchased from Sigma-Aldrich Pty. Ltd, Johannesburg 
South Africa; streptozotocin, D-glucose, citrate buffer, phosphate buffer, 
thiobarbituric acid, metaphosphoric acid chips, butylated hydroxytoluene and 
phosphoric acid.  
Metformin (Accord, Sandton, South Africa), insulin (Novo Nordisk, Norway), 
portable glucometers and glucose test strips (OneTouch Select, Zug, Switzerland) 
were purchased from a local pharmacy.  
A superoxide dismutase assay kit and a glutathione assay kit were purchased from 
Cayman Chemicals ( Michigan, USA). Insulin ELISA test kit was purchased from 
Mercodia Chemicals (Uppsala, Sweden). Halothane used to euthanize the animals 
were provided by the Biomedical Resourse Unit (BRU) of the University of 
KwaZulu-Natal, Durban, South Africa. 
 
2.2 Animal Treatment 
Male Sprague-Dawley rats weighing between 230-300 g were used in the study. 
Animals were housed at 7 rats per cage and had free access to food and drinking water 
for the duration of the study (56 days).  The rats were divided into 5 groups (n =7). 
The rats were maintained on a 12-hour dark/light cycle (08:00-20:00) in an air-
controlled room (temperature 25°C +/- 2°C, humidity 55 +/- 5%). Rats were fed 
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normal chow containing; protein, fibre, starch and calcium. All animals completed the 
study.  
 
2.3 Ethics  
Ethics approval was obtained from the Animal Research Ethics Committee of The 
University of KwaZulu-Natal. Ethics reference number: 078/14/Animal.  
 
2.4 Induction of Experimental Diabetes  
Diabetes was induced in groups B-E. Fasting glucose levels were taken prior to 
induction to ensure rats were not already diabetic. Diabetes was induced via a single 
intraperitoneal injection of streptozotocin (65 mg/kg body weight) from a stock 
solution at a concentration of 36 mg/ml.  Streptozotocin was dissolved in 0.1 M citrate 
buffer of pH 4.5. Citrate buffer was made using 10 mM of sodium citrate and 10 mM 
citric acid. Induction took place after overnight fasting. Diabetes was confirmed 48 
hours after the administration of streptozotocin solution.  Confirmation of diabetes 
diagnosis was carried out via fasting blood glucose tests. Blood was obtained via tail 
pricks and then blood glucose levels tested using glucostrips with a hand-held 
glucometer (Bayer Acensia). Rats with fasting blood glucose of 7.5 mmol/l and above 









2.5 Experimental Design 
Rats were divided into the following groups named A-E. Groups B-E were made type 
1 diabetic through intraperitoneal streptozotocin (STZ) injection as previous 
explained. 
 


















once daily, via 
oral gavage) 
 
A – Normal 
control 
    
B- Diabetic 
Control 
    
C – Insulin     
D- Metformin     
E-Metformin 
+ Ins 
    
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Rats were housed 7 per cage and had free access to food and water for the duration of 
the study. Bedding was changed daily. The rats were weighed daily and the weights 
obtained were recorded. The amount of water consumed was also measured daily and 
recorded. Random fasting blood glucose tests were carried out every 14 days with the 
results also being recorded. On day 51 of the study the rats were moved into 
metabolic cages for a period of 24 hours. Throughout this time urine was collected in 
a calibrated container attached to the cage. At the end of the 24 hours the urine 
collected was measured and then decanted into appropriate test containers before 
being stored at -80 °C for further analysis. On day 54 a glucose tolerance test was 
performed.  
 
On day 56 the animals were euthanized via halothane overdose. Blood samples were 
obtained via cardiac puncture and stored in appropriate test tubes. A portion of blood 
sample was placed in heparin test tubes while another portion placed in plain 
uncoated test tubes. Both tubes were centrifuged and the supernatant, either plasma or 
serum, was aliquoted out and placed in Eppendorf tubes. They were then stored at -80 
°C until further analysis. The kidney was quickly excised. The organs were washed in 
phosphate-buffered saline before being snap-frozen in liquid nitrogen and stored at -
80 °C until further analysis.     
 
2.6 Glucose Tolerance Tests 
On day 54 of the study, a glucose tolerance test was carried out. Before the GTT all 
animals were starved overnight and fasting blood glucose (FBG) concentrations were 
determined on the morning of the test before glucose administration. Rats received an 
intraperitoneal injection of 3.0 g/kg body weight of glucose in normal saline. Blood 
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glucose concentrations were then taken at 15, 30, 60, 90 and 120 minutes, 
respectively in all treatment groups.  
Area under the curve (AUC) was calculated from a blood glucose vs time plot and 
expressed as mmol/l x time (min), (AUC units).  
 
2.7 Electrolytes  
Electrolyte concentrations were determined in both serum and urine samples using  
Beckman Coulter Synchron Aqua CAL system for chloride, potassium and sodium 
diagnostic kits. For each sample, a volume of 40 μl sample was mixed with 1.32 ml of 
buffer solution (provided in diagnostic kit) in a ratio of 1 part sample to 33 parts 
buffer.  The concentrations of the various electrolytes were determined using indirect 
potentiometry. In the determination of potassium and chloride ions a potassium ion 
selective electrode or a solid state chloride electrode was used respectively in 
conjunction with a sodium reference electrode. In the determination of sodium ion 
concentration, 2 glass sodium electrodes were used, with one acting as a reference. 
Electrolyte buffer reagent as well as electrolyte reference reagents were provided in 
the diagnostic kits. The electrolyte buffer reagent was constituted with Tris buffer.    
 
2.8 Creatinine Concentrations  
Creatinine concentrations were determined in urine and serum sample by a Beckman 
Coulter diagnostic kit.  The system utilised a Jaffe method to determine the 
concentrations of the creatinine. Serum sample was combined with reagent solution in 
a ratio of 1:11 that is 20 μl of serum with 220 μl of reagent [75]. Urine samples were 
combined with reagent in a ratio of 1:73 that is 3 μl urine with 219 μl of reagent. The 
creatinine in the sample combined with picrate in an alkaline solution to form a deep 
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red creatinine-picrate complex. The colourimetric reaction was proportional to the 
amount of creatinine in the sample. The change in absorbance at 520 nm was 
measured. This absorbance was proportional to the concentration of creatinine in the 
sample.  
 
2.9 Creatinine Clearance 
Creatinine clearance was calculated using the following formula:  
      
                         
                         
   
                 
          
 
 
2.10 Urea  
Urea concentrations were determined in urine samples by a Beckman Coulter diagnostic 
kit. An enzymatic rate reaction is used to determine the concentration of the urea in the 
urine samples. The reaction is illustrated by the following chemical equations:  
Urea + H2O 
Urease  
2NH3 + CO2 






 + H20 
The urine samples were diluted in a ratio of 1 part urine to 100 parts reagent (3 μl urine to 
300 μl of reagent). The change of absorbance was measured by at 340 nm and was 
proportional to the concentrations of urea in the samples.  
 
2.11 Plasma Insulin 
An ultrasensitive rat insulin ELISA kit was used to determine the plasma insulin levels in 
the samples as per the manufacturer’s instruction using a 96-well microtitre plate. In 
brief, 25 μl of calibrator and samples were pipetted into each well before 100 μl of 
enzyme conjugate 1X solution was added. The plate was then incubated on a plate shaker 
(700-900 rpm) at room temperature (25°C) for 2 hours. The reaction volume was then 
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discarded before the plate was washed manually 6 times using 350 μl of the provided 
wash solution in each well. Thereafter, 200 μl of substrate tetramethylbenzidine (TMB) 
was added into each well before being incubated at room temperature for 15 minutes, 
after which 50 μl of stop solution was placed in each well. The plate was then placed on a 
plate shaker for approximately 5 seconds to ensure mixing. Optical density was read on a 
microplate reader (Biochron, EZ Read 400) at 450 nm and the results calculated. A 
calibration curve was drawn from the standard samples provided and the insulin plasma 
concentration of the test samples were read off the calibration curve via interpolation.   
 
2.12 Superoxide Dismutase (SOD) Assay 
Both manganese superoxide dismutase (MnSOD) and copper/zinc superoxide dismutase 
(CuSOD) were measured in kidney tissue samples. A SOD assay kit was used as per the 
manufacturer’s instructions using a 96-well microtitre plate. Kidney tissues were prepared by 
homogenisation 1:7 w/v in ice cold buffer, pH 7.2 (containing 1mM EGTA, 210mM 
mannitol, 70nM sucrose and 20mM HEPES). The samples of homogenised tissue in buffer 
were then centrifuged at 1500 xg for 5 minutes at 4 °C before being stored at -80 °C for 
further analysis.  
 
In brief, the assay was performed by adding 200 μl Radical detector (tetrazolium salt 
solution) and 10 μl of sample or standard into the well before initiating the reaction by adding 
20 μl of diluted xanthine oxidase to all the wells. When performing the assay for MnSOD, 
190 μl of radical detector and 10 μl of 3 mM potassium cyanide were added along with the 
sample and xanthine oxidase. The plate was then covered and incubated at room temperature 
on a plate shaker for 30 minutes. Absorbance was read at 450 nm using a microplate reader 
(Biochron, EZ Read 400) and the results calculated. The linearised rate (LR) of the standards 
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and samples were calculated by dividing standard A’s absorbance by all the other standards 
and samples. The linearised SOD standard rate was then plotted as a function of SOD activity 
(given) in order to produce a standard curve. The standard curve produced an equation which 
was used to calculate the SOD activity of the samples: 
     
 
  
   
                     
     
  
      
      
                    
Where LR  is Linearised Rate 
Reagents such as radical detector, xanthine oxidase and standards were provided by the kit 
and prepared by using the manufacturer’s instructions. 
 
2.13 Glutathione Concentrations  
A glutathione assay kit was used to determine the total glutathione concentrations in kidney 
homogenates as per the manufacturer’s instructions using a 96-well microtitre plate. Kidney 
tissues were prepared by homogenisation 1:7 w/v in cold buffer, pH 7 (containing 50 mM 
MES and 1 mM EDTA). The samples were then centrifuged at 10 000 xg for 15 minutes at 
4°C before the supernatant was removed and stored at -20°C in preparation for 
deproteination.  
 
For deproteination an equal volume of sample was mixed with metaphosphoric acid solution 
by vortexing. It was then centrifuged at 2000 xg for 2 minutes before the supernatant was 
collected. A solution of 4 M triethanolamine was prepared. This solution was then mixed 
with the supernatant in a ratio of 50 μl triethanolamine solution per 1ml supernatant.  
 
The assay was carried out by placing 50 μl of sample and standards into designated wells, 
then adding150 μl of Assay Cocktail (prepared using the manufacturer’s instructions) to each 
well before incubating in the dark on an orbital shaker and measuring the absorbance at 410 
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nm. Glutathione concentrations were then calculated by plotting a standard curve of 
glutathione concentration versus absorbance. The sample concentrations were the calculated 
through interpolation on the standard curve.   
 
 
2.14 Lipid Peroxidation - Plasma TBARS Assay  
Lipid peroxidation was quantified by measuring the concentrations of malondialdehyde 
(MDA) in plasma samples obtained from treatment animals. The assay was carried out 
according to the modified method of Phulukdaree et al [76]. In brief, a TBA/BHT solution 
was prepared using thiobarbituric acid (TBA) (1% w/v)/ 0.1 mM butylated hydroxytoluene 
(BHT). 
In a set of clean tubes 200 ul of samples were added to a solution of 500 μl of 2% phosphoric 
acid (H3PO4), 400μl of 7% H3PO4, 400μl of the TBA/BHT and 200μl of 1 M HCl 
respcetively. The tubes were incubated in boiling water (100°C) for 15 minutes before being 
cooled to room temperature. Once cooled, 1.5 ml of butanol was then added to each test tube 
and vortexed. Following vortexing, 200 μl of the top phase was transferred into a 96-well 
microtitre plate and read at 532 nm and 600 nm respectively using a microplate reader 
(Biochron, EZ Read 400). The plasma malondialedhyde (MDA) concentrations were then 
determined by using extinction coefficient 156 mM
-1
.       
 
2.15  Lipid Peroxidation - Renal Tissue TBARS Assay 
Tissue TBARS assay was carried out according to the modified method of Hermes-Lima et al 
[77]. Frozen kidney tissue was homogenised in a 1:10 (w/v) ratio with cold 1.1% phosphoric 
acid. A solution containing 1% TBA, 50 mM NaOH and 0.1 mM BHT was made for the 
assay. In a clean set of test tubes 400 μl of sample homogenate was added to 400 μl 
33 
 
TBA/BHT solution and 200 μl of 7% phosphoric acid (resulting in a final pH of 1.6). Test 
tubes were then incubated in a boiling water bath for 15 minutes before being cooled to room 
temperature. Once cooled, 1.5 ml of butanol was then added to each test tube and vortexed. 
Following vortexing the solution splits into 2 phases, 200 μl of the top phase from each test 
tube was transferred into a 96-well microtitre plate and read at 532 nm and 600 nm 
respectively using a microplate reader (Biochron, EZ Read 400). The plasma MDA 
concentrations were then determined by using extinction coefficient 156 mM
-1
.       
  
2.16 Statistical Significance  
Data was presented as mean ± SD and analyzed using the statistical software, GraphPad 
Prism (San Diego, USA) version 5.0. Student t-tests or 1-way ANOVA were carried out 








3.1 NATURAL GROWTH MEASURED BY WEIGHT GAIN 
Animals were weighed daily throughout the study period. These weights were plotted against 
time to show the growth trend.  
 
Untreated diabetic control animals experienced negative weight gain compared to the normal 
controls (Fig. 5). However, treatment with insulin or a combination of insulin + metformin 
resulted in steady positive weight gain. Metformin treatment alone did not improve weight 
loss compared to the untreated diabetic controls. 
 
  
Figure 5: Animal live weights over time. Weight changes during treatment period for the 
different treatment groups   
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The difference between final weight and initial weight was calculated per treatment group. 
The average change in weight between the normal control and the untreated diabetic control 
groups was highly significant (p < 0.0001) (Fig. 6). Both the insulin and the metformin + 
insulin group had significantly (p<0.0001) increased weight compared to the untreated 
diabetic control group (Fig. 6). However, no significant difference occurred between the 











Figure 6: Changes in animal live weights. Animals were weighed at the beginning and at the 
end of the study and the differences in weights calculated.  *** p < 0.0001 compared to 
normal control. ### p < 0.05 compared to untreated diabetic control. $$$ p< 0.0001 



























































3.2 WATER CONSUMPTION 
Water consumption was measured daily and the average amount per animal in each treatment 
group per day was calculated.   
Untreated diabetic animals consumed significantly (p<0.0001) more water compared to the 
normal controls suggesting increased polydipsia. Treatment with insulin, with or without 
metformin reduced the amount of water consumed by the animals compared to the untreated 














Figure 7: Average Daily Water Consumption in Designated Treatment Groups, calculated by 
taking the total volume drunk by the group and dividing by the total number of rats in the 























































3.3 URINE OUTPUT 
Untreated diabetic controls produced significantly more urine over 24 hrs than the normal 
controls (p < 0.001). Insulin with or without metformin insignificantly reduced urine output 













Figure 8: Average 24 hour urine output. Output was measured by placing the test animals in 
metabolic cages for 24 hours. Metabolic cages had plastic vessels attached to specifically 

























































3.4 FASTING BLOOD GLUCOSE 
 
Diabetic animals had significantly (p< 0.0001) higher fasting blood glucose levels compared 
to the normal controls. Blood glucose levels for the diabetic controls as well as the metformin 
group, increased as the study progressed. Treatment with metformin or insulin did not 




Figure 9: Fasting blood glucose concentrations measured in each designated group. Blood 
was obtained via tail prick and glucose levels measured using a hand held glucometer. 














































3.5 GLUCOSE TOLERANCE TEST 
 
Diabetic animals had significantly higher (p < 0.0001) fasting blood glucose levels compared 
to normal controls (Fig. 10a). Untreated diabetic controls and the metformin group had high 
basal glucose levels compared to the normal control. Following the intraperitoneal injection 
of glucose, all groups experienced an initial spike in blood glucose levels but blood glucose 




Figure 10a: Glucose Tolerance Tests. Blood glucose concentrations plotted against time after 
the animals were injected intraperitoneally with glucose (3.0g/kg) in normal saline, blood 
































Calculated AUC for the untreated diabetic controls was significantly (p< 0.0001) higher 
compared to the normal controls (p<0.0001). Treatment with metformin + insulin resulted in 
significantly (p < 0.05) reduced AUC when compared to untreated diabetic rats (p<0.05) 
(Fig. 10b). Insulin also reduced AUC compared to untreated diabetic controls, however this 
was insignificant.   Treatment with metformin alone resulted in high AUC levels and had no 















Figure 10b: Calculated  area under the curve (AUC) from blood glucose vs time plots. AUC 
was measured as mmol/l x time to give AUC units. *** p< 0.0001 in two-tailed t-test for  
control group versus diabetic control group. # p < 0.05  in a two –tailed t-test for metformin+ 
























































3.6 FASTING PLASMA INSULIN 
Untreated diabetic rats exhibited significantly (p<0.0001) lower plasma insulin levels 
compared to normal controls (Fig. 11). However, treatment with insulin or metformin + 
insulin resulted in significantly (p<0.05) elevated plasma insulin levels compared to untreated 













Figure 11: Fasting plasma insulin concentration. Plasma insulin concentrations were 
measured in blood obtained via cardiac puncture. ***p < 0.0001 compared to normal control 





























































3.7  SERUM AND URINARY ELECTROLYTES 
 




 output was significantly (p<0.0001) reduced in untreated diabetic animals 
compared to normal controls (Fig 9a). However treatment with insulin or metformin (p < 
0.05) or metformin + insulin (p < 0.0001) significantly improved urinary Na
+
 excretion 










Figure 12a: Urinary Na
+
 output. Animals were placed in metabolic cages for 24 hours and 
urine collected for analysis. Electrolyte concentrations were determined using diagnostic kits. 
*** p< 0.0001 compared to normal control. 
### 
p<0.0001 compared to untreated diabetic 


























































 output was significantly (p< 0.0001) reduced in untreated diabetic controls 
compared to normal controls (Fig 9b). However treatment with insulin or insulin + metformin 
significantly (p < 0.05) increased urinary K
+













Figure 12b: Urinary K
+
 output. Animals were placed in metabolic cages for 24 hours and 
urine collected for analysis. Electrolyte concentrations were determined using diagnostic kits. 
*** p< 0.0001 compared to normal controls,  
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 output was significantly (p < 0.0001) reduced in diabetic controls compared to 
normal controls (Fig 9c). However, treatment with metformin + insulin significantly (p < 




 excretion compared to untreated 













Figure 12c: Urinary Cl
-
 output. Animals were placed in metabolic cages for 24 hours and 
urine collected for analysis. Electrolyte concentrations were determined using diagnostic kits. 
*** p< 0.0001 for diabetic control versus normal control.  @@ p < 0.01 compared to 






















































3.7.2 SERUM ELECTROLYTES 
Diabetic controls exhibited significantly (p <0.0001) reduced levels of serum Na
+
 compared 
to normal controls. Treatment with metformin + insulin slightly but significantly (p< 0.05) 
increased serum Na
+










Figure 13a: Serum Na
+
 concentrations. Serum electrolyte concentrations were determined 
using diagnostic kits. *** p < 0.0001 for untreated diabetic control versus normal control. 























































 levels were significantly elevated (p =0.01) in untreated diabetic controls 
compared to normal controls. Treatment with insulin with or without metformin significantly 
(p<0.05) reduced serum K
+ 











Figure 13b: Serum K
+
 concentrations. Serum electrolyte concentrations were determined 
using diagnostic kits. * p= 0.01 compared to normal control. ## p < 0.05 compared to 



























































Untreated diabetic controls exhibited significantly (p<0.0001) reduced serum Cl
-
 levels when 
compared to normal controls. Treatment with insulin or metformin did not improve serum Cl
- 











Figure 13c: Serum Cl
- 
concentration. Serum electrolyte concentrations were determined using 























































3.8 SERUM AND URINARY CREATININE 
3.8.1 URINARY CREATININE 
Urinary creatinine output was significantly (p < 0.0001) reduced in untreated diabetic animals 
compared to normal controls. However, treatment with insulin with or without metformin 
significantly (p < 0.01) increased urinary creatinine excretion in diabetic animals compared to 
untreated diabetic animals (Fig 11). However, treatment with metformin alone did not 














Figure 14: Urinary creatinine output. Creatinine levels were measured in urine samples which 
were collected over a period of 24 hours. *** p< 0.0001 for untreated diabetic controls versus 






















































3.8.2) Serum Creatinine/ Weight 
As muscle mass decreases so does the concentration of creatinine as creatinine is a product of 
muscle metabolism. Serum creatinine was therefore corrected for weight differences across 
the groups; this was done by dividing the serum creatinine concentration by the final weight 
of each rat in each designated treatment group.    
Serum creatinine to body weight ratio was significantly (p<0.0001) higher in the untreated 
diabetic rats compared to the normal controls (Fig. 15). However treatment with insulin with 
or without metformin significantly (p<0.05) reduced the serum creatinine to weight ratio 









Figure 15: Serum Creatinine concentrations expressed as a ratio of creatinine to weight. 
Serum concentrations were divided by final weight of animal. *** p<0.0001 untreated 

























































3.9 UREA  
Untreated diabetic control rats had significantly (p <0.0001) reduced urinary urea output 
compared to normal controls (Fig. 16). However, treatment with metformin + insulin 
significantly (p<0.005) raised urinary urea output compared to the untreated diabetic controls 
(Fig. 16). Treatment with insulin or metformin alone did not significantly increase urea 










Figure 16: Urinary urea output. Animals were placed in metabolic cages for 24 hours and the 
urine collected. Urinary urea content was measured using diagnostic kits. *** p< 0.0001 





















































3.10 Calculated Creatinine Clearance  
Untreated diabetic controls had significantly (p<0.05) reduced creatinine clearance. However 
treatment with metformin + insulin significantly (p< 0.01) increased creatinine clearance 











Figure 17: Calculated creatinine clearance. Creatinine clearance was calculated using the 
formula: (Cr conc urine/ Cr conc serum) x (urine volume/ time). *p<0.05 compared to normal 

























































ASSESSMENT OF OXIDATIVE STRESS 
 
3.11 SUPEROXIDE DISMUTASE 
 
MnSOD activity was significantly increased in untreated diabetic controls (p< 0.005) 
compared to normal controls (Fig 15a). Treatment with metformin, with or without insulin, 
significantly (p<0.001) reduced MnSOD activity. Treatment with insulin alone however, did 











Figure 18a: Manganese Superoxide dismutase activity in renal tissue. Tissue was 
homogenised and measured as previously explained. *** p < 0.005 compared to normal 
































































Cu/ZnSOD activity was not significantly different between untreated diabetic and normal 
controls. Treatment with metformin + insulin resulted in a slightly reduced and significant 










Figure 18b: Assessment of Copper/Zinc superoxide dismutase activity in renal tissue. Tissue 


































































3.12 PLASMA LIPID PEROXIDATION 
Untreated diabetic controls experienced significant (p<0.0001), elevation of plasma levels of 
malondialdehyde compared to normal controls (Fig. 19a). Treatment with insulin, metformin 
or metformin + insulin significantly (p<0.0001) reduced plasma malondialdehyde 









Figure 19a: Plasma concentrations of Malondialdehyde. Plasma samples were assayed and 
malondialdehyde concentrations determined.  ***p< 0.0001 compared to normal control, 







































































3.13 RENAL TISSUE LIPID PEROXIDATION 
 
Untreated diabetic controls exhibited significantly (p= 0.001) increased levels of renal tissue 
malondialdehyde concentrations compared to normal controls (Fig. 19 b). However, 
treatment with metformin, with or without insulin, resulted in significantly (p<0.0001) 














Fig 19b: Renal tissue concentrations of malondialdehyde. Renal tissue was homogenised and 
then assayed for lipid peroxidation concentration. *** p = 0.001 compared to normal 
controls. ## p< 0.0001compared to untreated diabetic controls. $ p< 0.05 compared to 



































































3.14 RENAL TISSUE GLUTATHIONE CONCENTRATIONS 
 
Glutathione concentrations were significantly (p<0.05) reduced in untreated diabetic controls 
compared to normal controls. However, treatment with metformin (p<0.05) or metformin + 













Figure 20: Renal tissue glutathione concentrations. Tissue was homogenised and glutathione 
concentrations measured as previously explained. *p<0.05 compared to normal control. #p< 





























































DISCUSSION AND CONCLUSION 
 
In this study we aimed to investigate whether metformin ameliorates aspects of diabetic 
nephropathy and improves renal function when added to insulin in the treatment of T1D. The 
results obtained indicate that metformin does have positive effects on renal function; there 
were increased concentrations of urine electrolytes with a concomitant decrease in serum 
electrolytes. There was improved creatinine clearance and an improved oxidative stress state. 
This was evident via a reduction in SOD activity and a reduction in malondialdehyde 
concentration when rats were treated with adjunctive metformin. However, metformin does 
not improve glucose intolerance in a type 1 diabetic model. Metformin improved oxidative 
stress associated with diabetes and prevented renal function deterioration. This adds further 
evidence to existing studies which claim that metformin possesses renopreotective properties 
[29, 68].  
 
4.1 Glucose Intolerance 
Type 1 diabetes was induced in the treatment groups via an intraperitoneal injection of 
streptozotocin at a dose of 65 mg/kg. At this dose streptozotocin, a cytotoxic glucose 
analogue completely destroys the pancreatic beta-cells [78]. These cells are responsible for 
insulin secretion under normal conditions. Streptozotocin is taken up selectively into the beta-
cells through the GLUT-2 transporter and accumulates in the beta cells. Once in the cell, 
streptozotocin splits into glucose and methylnitrosurea [78]. The metylnitrosurea moiety 
possesses DNA alkylating activity. This causes DNA damage and ultimately leads to β-cell 
death [78]. At a dose of 65 mg/kg, streptozotocin causes complete beta-cell destruction [79]. 
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Fasting plasma insulin levels were highest in the normal controls and lowest in the untreated 
diabetic controls (Fig.11). This was expected as there was total beta-cell destruction after 
streptozotocin administration in the diabetic groups. The groups treated with insulin, with or 
without metformin, had increased concentrations of plasma insulin compared to the diabetic 
control but lower than the normal control (Fig. 11). A reason for this is that animals were 
fasted overnight before being euthanized and did not receive treatment the morning of the 
euthanasia. Therefore plasma insulin levels reflected residual long-acting insulin still present 
in the plasma from the prior dose.   
Classic T1D signs were displayed by all treatment groups that were made diabetic. These 
signs included weight loss (Fig. 6), polyurea (Fig. 8), polydipsia (Fig. 7) and high glucose 
levels (Fig. 9). This was expected because insulin is an anabolic hormone which promotes 
tissue growth. Therefore, in its absence the body goes into a catabolic state and rapid weight 
loss ensues [80]. As glucose cannot be taken up by the cells because of a lack of insulin, the 
body resorts to breaking down fat and protein for energy instead, this leads to muscle wasting 
[81]. Weight loss and muscle wasting are classic signs of type 1 diabetes. This accounts for 
the weight loss seen in the diabetic controls and the diabetics treated with metformin (Fig. 5 
and Fig. 6).  When insulin was present as in the normal controls, the insulin group and the 
group treated with metformin + insulin, animals’ weight increased (Fig. 6). This is because 
insulin is a powerful anabolic hormone and causes weight gain. However, the diabetic control 
group and the group treated with metformin alone experienced overall weight loss due to a 
lack of insulin presence. Groups which were treated with insulin alone or a combination of 
insulin & metformin picked up weight steadily throughout the study, which was significant 
when compared to the untreated diabetic control (Fig. 6). Natural growth dipped and weight 
fell on days where rats were fasted overnight in preparation for Fasting Blood Glucose (FBG) 
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tests to be carried out (Fig. 5). As soon as normal diet was resumed normal growth patterns 
continued.   
All diabetic groups in the study displayed classic polydipsia and polyuria. The 
hyperglycaemia present in T1D causes increased glucose concentrations in the renal tubules 
of the kidney, this leads to osmotic diuresis and polyuria which in turn stimulates polydipsia 
[80]. Polydipisia arises due to intracellular dehydration caused by elevated glucose levels [80, 
81]. Both polyuria and polydipsia are classic symptoms of type 1 diabetes. Groups treated 
with insulin alone or a combination of metformin + insulin had lower levels of urine output 
compared to the diabetic control group (Fig. 8). This indicates that there were reduced levels 
of glucose present and hence, less osmotic diuresis and reduced urine output. Metformin, a 
drug commonly used in type 2 diabetes to reduce blood glucose levels had no effect when 
used alone on polyuria and polydipsia in this T1D model. This too could have been expected. 
Metformin has no diuretic properties and is an insulin sensitizer which requires the presence 
of insulin in order to lower glucose levels. Therefore, when metformin was used alone, 
hyperglycaemia remained high and the classic T1D signs persisted.   
Fasting blood glucose levels were measured every 14 days throughout of study (Fig 9). 
Diabetic controls displayed progressively higher blood glucose levels. The insulin group and 
the group treated with metformin + insulin displayed lower blood glucose levels compared to 
the diabetic control. Fasting blood glucose levels for insulin group and the metformin + 
insulin group were relatively high compared to the normal controls. A suggested reason for 
this is that insulin treatment was not given prior to testing as it was intended that long-term 
residual effects of treatment be investigated and not short-term immediate effects. Hence, no 




When glucose tolerance tests were carried out the insulin treated and the metformin + insulin 
treated groups had a better response to the glucose dose compared the untreated diabetic 
control group. Between the two groups, the group treated with metformin + insulin started at 
a lower baseline glucose level and returned almost back to baseline faster. When AUC for the 
GTT was calculated, the metformin + insulin group had a significantly lower AUC compared 
to the untreated diabetic control (Fig. 10b). This indicates that the group treated with 
metformin + insulin was more tolerant towards a bolus glucose dose 
In our study metformin enhanced the effects of insulin. Fasting blood glucose levels in the 
metformin + insulin group were lower than those in the group treated with insulin alone (Fig. 
9); however, this difference was not statistically significantly. Treatment with metformin 
alone showed no improvement in glucose control. This was expected as metformin requires 
insulin in order to carry out its glucose lowering effects.  
In other studies conducted where metformin was added as an adjunctive therapy to insulin in 
T1D, similar results were obtained [49, 82]. Studies have shown that when metformin is 
added to insulin for T1D it is associated with a decrease in the insulin dose required to 
maintain normal glycaemic levels [49, 50, 58, 82]. This is due to metformin’s insulin 
sensitising activity. However, despite lowering insulin requirements, there is no long term 
decrease in HbA1c levels associated with adjunctive therapy in T1D [49, 50, 58]. The 
reasoning for this is that when metformin was added to insulin therapy in human based 
studies, patients reduced their insulin dose in order to maintain usual HbA1c levels [49].  
Metformin enhances the effects of insulin by upregulating the translocation of glucose 
transporters GLUT-4 and GLUT-2 to the hepatic plasma membrane. Consequently this 
causes an increase in glucose uptake which further leads to increased glycogen synthesis and 
decreased gluconeogenesis [48]. It is also thought that metformin directly inhibits 
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gluconeogenesis through its effects on the mitochondrial electron transport chain and AMPK 
[48, 51, 83]. Metformin, through its inhibition of the mitochondrial electron transport chain, 
causes an increase in the AMP:ATP ratio. This results in an increase in AMPK activity and 
therefore glucose uptake is promoted and gluconeogenesis in inhibited. An increase in AMP 
furthermore leads to the suppression of adenylate glucose which down regulates PKA, a 
downstream activator of gluconeogenesis gene expression [51]. This is illustrated in our 
results where the groups treated with insulin or a combination of metformin + insulin had an 
average lower fasting blood glucose levels and a lower AUC for the glucose tolerance tests.   
 
4.2 Renal Function 
The kidneys’ most important function is to maintain fluid and electrolyte balance within the 
body [84]. Our results showed that electrolyte (sodium, potassium and chloride) levels in the 
urine were significantly higher in the normal controls compared to the untreated diabetic 
control group (Fig 12 a, b, c).  As renal function deteriorates there is increased retention of 
electrolytes and less being excreted in the urine. Retention of electrolytes can cause an 
electrolyte imbalance and may affect health. This can lead to a retention of waste products 




) which can have serious consequences such as 
adverse cardiac outcomes [84]. Hyperkalemia and hypernatraemia are common problems in 
renal dysfunction. Hyperkalemia can lead to serious complications such as hypotension and 
ventricular dysrhythmias which impact on the cardiovascular system [84]. Potassium and 
sodium levels in the urine, were significantly higher in both the insulin group and the 
metformin + insulin group compared to diabetic control (Fig. 12a, 12b), this possibly 
indicates that renal function was better preserved in these groups.  
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Serum potassium concentrations were elevated compared to normal controls; this was 
expected due to the decrease in potassium electrolyte excretion in urine (Fig 13. b). However, 
sodium serum concentrations were decreased in diabetic controls compared to normal 
controls (Fig. 13a). A suggested explanation for this is that due to an increased serum 
concentration caused by renal impairment and decreased electrolyte excretion via the urine, 
an electrolyte shift may have occurred where electrolytes shifted out the serum and entered 
the intracellular space instead. An osmotic shift may have also occurred due to cellular 
dehydration.    
As creatinine concentrations were corrected for weight variations between groups it was seen 
that diabetic groups had higher levels of serum creatinine compared to the normal control 
(Fig. 15). Both the metformin + insulin group and the insulin treated group produced 
significantly lower levels of serum creatinine compared to the untreated diabetic controls. An 
elevated serum creatinine indicates impaired kidney function due to inadequate clearance. As 
the kidneys are responsible for creatinine clearance, as renal function deteriorates serum 
creatinine levels begin to rise. Investigating serum creatinine concentrations provides an 
indication of kidney function. Creatinine is a product of muscle metabolism and under normal 
circumstances is filtered at the glomerulus and also in small amounts in the proximal tubule 
[85, 86]. If renal function is compromised, creatinine will not be fully excreted and may 
accumulate in the body. This explains the results we obtained. In the insulin treated and the 
metformin + insulin treated groups, kidney function experienced less deterioration and more 
resembled the normal control. They had significantly less serum creatinine compared to the 
untreated diabetic control (Fig. 15). Creatinine levels would also rise in the presence of 
increased muscle catabolism. This is common in T1D where in the absence of insulin the 
body is unable to utilise glucose for energy and resorts to fat and muscle breakdown instead.  
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Creatinine clearance is a good estimator of glomerular filtration rate. Creatinine clearance 
measures the volume of plasma cleared of creatinine by the proximal tubule as well as 
excreted by the glomerulus per minute [85]. As it is not possible to measure glomerular 
filtration rate (GFR) directly, creatinine clearance is used to estimate GFR. GFR measures the 
rate at which substances are filtered out of the blood from the glumeruli and into the 
Bowman’s capsule of the nephrons [85]. GFR provides a good indicator of renal function 
with a reduction in GFR indicating functional impairment of the nephrons [86-88]. As renal 
function decreases, creatinine clearance as well as GFR also decreases. In this study 
creatinine clearance was highest in the normal controls and the group treated with metformin 
+ insulin (Fig. 17). The untreated diabetic control group produced the lowest creatinine 
clearance rate. When metformin was combined with insulin, creatinine clearance significantly 
improved. This indicates that treatment with metformin + insulin helped preserve renal 
function and caused an improvement in creatinine clearance.    
Urea is a water-soluble molecule which is an end product of protein metabolism [87]. It is 
found highly concentrated in the urine. If kidney function is compromised one would expect 
a decrease in the concentrations of urea found in the urine. Urea concentrations were 
significantly lower in the untreated diabetic control group compared to the normal control 
group. The group treated with metformin + insulin displayed significantly increased 
concentrations of urea compared to the untreated diabetic control (Fig. 16). It is known that 
gluconeogenesis in the kidney is also closely linked to ureagenesis. This is to compensate for 
the increase in nitrogen and amino acids created in gluconeogenesis [87]. It is also thought 
that glucagon, the hormone which promotes gluconeogenesis also stimulates urea synthesis 
by the liver [87]. Therefore one would initially expect the urea concentrations to be elevated 
in the diabetic control group and in groups where glucose control was not fully obtained. 
However, in our results urea concentrations were elevated in the normal control group and 
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lower in the untreated diabetic control group. There are two possible explanations of this. 
Firstly, the diabetic groups produced more urine compared to the untreated control group 
suggesting the presence of polyuria caused by hyperglycemia. Although there possibly could 
have been more urea in the diabetic groups, concentration remained low due to an increased 
urine volume (a dilutionary effect). Secondly, renal function has probably deteriorated in the 
diabetic groups and the kidney’s ability to filter out this by-product of protein metabolism 
may have been compromised, resulting in decreased urea concentration in the urine. Added to 
this is the reduced body mass found in the diabetic control group and the group treated with 
metformin. As urea is an end-product of protein metabolism a reduced body mass would also 
lead to reduced levels of urea being produced and excreted and could have also contributed to 
the finding. Unfortunately serum urea was not investigated in this study; however, one would 
expect serum urea to be elevated due to decreased urea excretion in urine.  
Previous studies have shown metformin to possess renoprotective effects. Metformin has 
been shown to attenuate gentamycin induced nephropathy, as well as protect against 
podocyte and renal tubular injury [29, 31, 68, 69]. It is thought to achieve this by reducing 
oxidative stress via activation of AMPK and inhibiting complex 1 of the mitochondrial 
electron transport chain [68, 69].  Some in vitro studies have shown that when metformin is 
incubated along with an AMPK inhibitor, metformin’s antioxidant effects were completely 
abolished [31]. Piwkowska et al. (2010) demonstrated that podocytes incubated with 
metformin inhibited the formation of superoxide to a similar degree to when podocytes were 
incubated with an NADPH- oxidase inhibitor and further showed that when compound C (an 
AMPK inihibitor) was administered, metformin had no effect on NADPH oxidase activity 
[31]. Hence there could be a link between AMPK activation and NADPH-oxidase superoxide 




As to the best of my knowledge, no studies have examined the effects of metformin on 
electrolyte concentrations, creatinine clearance or urea concentration before in relation to the 
development of renal impairment in T1D.  
 
4.3 Oxidative Stress 
Hyperglycemia has been shown to decrease the body’s total antioxidant capacity and increase 
oxidative stress [20]. This increase in oxidative stress together with prolonged hyperglycemia 
increases the prevalence of diabetic complications [16, 21]. SOD has been shown to be a 
powerful antioxidant and therefore an indicator of oxidative stress [3, 18]. Manganese 
superoxide dismutase is found in the mitochondria whereas copper/zinc superoxide dismutase 
is commonly found in the cytoplasm. Superoxide dismutase activity was measured in order to 
investigate the state of oxidative stress present.  
In our study the normal controls displayed significantly less SOD activity, with the untreated 
diabetic control group displaying the most activity (Fig 18 a, b). The group treated with 
metformin + insulin as well as the group treated solely with metformin had significantly less 
Mn-SOD activity compared to the untreated diabetic control (Fig. 18 a). Groups treated with 
metformin, with or without insulin, had even lower SOD activity than the normal control. 
This is because metformin acts predominantly in the mitochondria [52, 70]. Metformin acted 
to decrease the oxidative stress via its action on AMPK and the ETC, therefore SOD activity 
was reduced. Metformin inhibits complex 1 of the mitochondrial ETC which leads to 
inhibition of mitochondrial ROS production [45]. As there was more oxidative stress present 
in the diabetic control, there was an increase in SOD activity in order to combat the oxidative 
stress. In the normal control there was reduced oxidative stress therefore SOD activity 
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remained low. Superoxide dismutase is an inducible enzyme and therefore; in non oxidative 
stress conditions will not be activated.  
 
Copper/zinc SOD is predominantly found in the cytosol. Superoxide dismutase activity was 
slightly decreased in the metformin + insulin group as well as the normal control group; 
however, the difference was of little significance (Fig 18 b). This is likely explained by the 
fact that metformin does not act in the cytosol but rather in the mitochondria. Therefore, 
Cu/Zn-SOD activity was not reduced to any great extent as activity was limited to the 
mitochondria and not the cytosol.   
 
Malondialdehyde (MDA) is a frequently used indicator of lipid peroxidation and is a 
biomarker for oxidative stress. Plasma malondialdehyde concentration is a good indicator of 
the presence of total oxidative stress. The present study showed that MDA plasma 
concentrations were highest in the diabetic control group and lowest in the group treated with 
metformin + insulin (Fig. 19 a). All groups had significantly lower MDA concentrations 
when compared to the untreated diabetic control group. This further suggests that metformin 
operates as an antioxidant to reduce oxidative stress. Treatment with metformin, with or 
without insulin greatly reduced MDA concentrations. The same pattern emerged when MDA 
concentrations were measured in renal tissue (Fig. 19 b). MDA concentrations were highest 
in the untreated diabetic control group. The normal controls as well as the groups treated with 
metformin and a combination of metformin + insulin had significantly reduced levels of 
MDA compared to the diabetic controls. These results further strengthen the thought that 
metformin reduced oxidative stress through antioxidant properties. 
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Glutathione is an important antioxidant and scavenger of ROS [19, 21]. GSH levels were 
elevated in the groups treated with metformin and lowest in the untreated diabetic control 
group (Fig. 20). Metformin + insulin treatment resulted in highly significant increases in 
GSH levels compared to the diabetic control. Despite GSH being a highly inducible enzyme, 
oxidative stress was highest in the diabetic control group which resulted in GSH being low. 
Metformin, potentially acting as an antioxidant, protected against oxidative stress; and 
thereby preserved GSH levels. Under hyperglycaemic conditions where oxidative stress is 
high, GSH levels are depleted. NADPH is used by aldose reductase in the polyol pathway of 
oxidative stress to form sorbitol. Glutathione reductase is therefore unable to use NADPH in 
order to reduce GSSG to GSH, leading to a depletion in the GSH pool [18, 22]. Therefore 
results in the present study indicate that oxidative stress was highest in the untreated diabetic 
control group and significantly reduced in the groups treated with metformin.   
 
4.4 CONCLUSIONS 
In this study we tested the ability of metformin to reduce or ameliorate diabetes associated 
renal impairment when used as an adjunct to insulin therapy in type 1 diabetes. The data 
presented here indicates that metformin does not improve glycaemic control in type 1 
diabetes but does have protective effect against the development of renal impairment and 
diabetic nephropathy. There was an improvement in creatinine clearance, and there were 
increased concentrations of urine electrolytes with concomitant decreases in serum 
electrolytes. Also, when used in conjunction to insulin, metformin reduces oxidative stress 
and helps preserve renal function in diabetic rats. Treatment with metformin in conjunction 
with insulin reduced SOD activity, reduced MDA concentration in plasma and renal tissue as 
well as increased glutathione concentration in renal tissue.   
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4.5 STUDY LIMITATIONS 
Short comings of the study include a lack of histological tests and diabetic nephropathy 
markers such as albumin levels. However, this study does prove a need to further advocate 
the use of metformin in T1D for the alleviation of diabetic complications such as diabetic 
nephropathy and renal impairment. Further studies are warranted to investigate fully the use 
of metformin in T1D to prevent or delay the onset of diabetic nephropathy and the other 
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Article Type: Research Article
Full Title: GRAPEFRUIT-DERIVED FLAVONOID NARINGIN IMPROVES KETOACIDOSIS AND
LIPID PEROXIDATION IN TYPE 1 DIABETES RAT MODEL
Short Title: Naringin ameliorates diabetic ketoacidosis
Corresponding Author: Peter MO Owira
University of Kwazulu-Natal
Durban, KZN SOUTH AFRICA
Keywords: Naringin, antioxidants, ketoacidosis, hyperglycemia.
Abstract: Background
Hypoglycemic effects of grapefruit juice are well known but the effects of naringin, its
main flavonoid on glucose intolerance and metabolic complications in type 1 diabetes
are not known.
Objectives
To investigate the effects of naringin on glucose intolerance, oxidative stress and
ketonemia in type 1 diabetic rats.
Methods
Sprague-Dawley rats divided into 5 groups (n=7) were orally treated daily with 3.0
ml/kg body weight (BW)/day of distilled water (group 1) or 50 mg/kg BW of naringin
(groups 2 and 4, respectively). Groups 3, 4 and 5 were given a single intra-peritoneal
injection of 60 mg/kg BW of streptozotocin to induce diabetes. Group 3 was further
treated with subcutaneous insulin (4.0 IU/kg BW) twice daily, respectively.
Results
Stretozotocin (STZ) only-treated groups exhibited hyperglycemia, polydipsia, polyuria,
weight loss, glucose intolerance, low fasting plasma insulin and reduced hepatic
glycogen content compared to the control group. Furthermore they had significantly
elevated Malondialdehyde (MDA), acetoacetate, β-hydroxybutyrate, anion gap and
significantly reduced blood pH and plasma bicarbonate compared to the control group.
Naringin treatment significantly improved Fasting Plasma Insulin (FPI), hepatic
glycogen content, malondialdehyde, β-hydroxybutyrate, acetoacetate, bicarbonate,
blood pH and anion gap but not Fasting Blood Glucose (FBG) compared to the STZ
only-treated group.
Conclusions
Naringin is not hypoglycemic but ameliorates ketoacidosis and oxidative stress.
Naringin supplements could therefore mitigate complications of diabetic ketoacidosis.







Response to Reviewers: 5. Review Comments to the Author
Please use the space provided to explain your answers to the questions above. You
may also include additional comments for the author, including concerns about dual
publication, research ethics, or publication ethics. (Please upload your review as an
attachment if it exceeds 20,000 characters)
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Reviewer #1: The present study reported Narigin may improve the oxidative stress and
ketoacidosis but have no effect on glucose tolerance in type 1 diabetic rat, which is
interesting and challenging. There are still some concerns need to be addressed.
1.In the current study, hypoglycemic effect of Naringin was not observed which was
inconsistent with other reports. More discusses are needed to interpret the increased
insulin and hepatic glycogen but no influence on glucose by Naringin treatment. Would
the potential hypoglycemic effect of Naringin exert on mild condition? Mild diabetic rats
are suggested to use as an additional group (e.g.STZ 35 mg/kg). Have the authors try
to confirm its insulinotropic effect on cell lines? Or other pathways for example,
stimulating the secretion of incretin when oral GTT performed? (J endocrinology,
2013,217:185-196)
Response:
As highlighted in our discussion, hypoglycemic effects of naringin so far demonstrated
are apparent in type 2 diabetes rat models where there is some residual insulin
secretion. We have previously shown that without insulin, naringin does not exert
hypoglycemic effects {J Cardiovasc Pharmacol. 2012 Feb;59(2):133-41; Accepted
Manuscript in PLOS ONE (PONE-D-15-28866R2)}. Enhanced insulin secretion in
normal non-diabetic rats treated with insulin could be attributed to antioxidant potential
of naringin that reduces reactive oxygen species concentrations in the pancreatic β-
cells leading to increased ATP production and insulin secretion (our as yet unpublished
work on the effects of naringin on insulin secretion in RIN-5F cell lines). Insulinotropic
effects of naringin have not previously been fully investigated but is a possibility. DPP-
IV inhibitory potential of naringin has recently been described (Diabetes Res Clin Pract.
2012 Jul;97(1):105-11) suggesting that naringin could have increased insulin secretion
in these rats by increased GLP-1 half-life. However, enhanced insulin secretion was an
unexpected finding that was beyond the scope of our study in the interim.
Similarly, we unexpectedly found that naringin significantly increased glycogen content
in non-diabetic rats compared to controls. However, this is not surprising considering
our recent finding (Eur J Nutr. 2016 Mar;55(2):631-638) that grapefruit juice
significantly increases hepatic glycogen content in non-diabetic and diabetic compared
to controls and diabetic rats, respectively by activating glucokinase and down-
regulating hepatic activities of key gluconeogenic enzymes, PEPCK and G-6-Pase.
Interestingly, insulin treatment of diabetic rats did not significantly increase glycogen
concentrations compared to untreated diabetic rats. Naringin is the predominant
bioflavonoid in the grapefruit juice and we are convinced that in the previous and
present study, it activated glycogen synthase via AMPK upregulation like metformin
(Arch Biochem Biophys. 2012 Feb 1;518(1):61-70). These points have been
incorporated into the discussion in the present manuscript.
2.STZ treatment may take some days to exert effects stably (generally 5-7 days). Why
the authors confirm the blood glucose on day 3 after STZ treatment? Similarly,
treatments were performed immediately following the confirmation. STZ induced
diabetic model may lead to wide variations in weight and FBG. Some rats may display
very severe symptom (e.g. FBG > 18 mmol/L, weight <180 g) following the STZ
treatment. How did authors deal with this? Details of grouping are needed.
Response:
We have been consulted by other research groups on how we manage to induce
stable hyperglycemia within 24 hrs of administering STZ without animal deaths. In our
experience, the animals have to be fasted overnight, and STZ dissolved in 0.2 ml of 0.1
M citrate buffer, pH 4.5.  It is critical that be buffer be made a fresh and the pH kept at
4.5 without adjusting with either NaOH or NaCl. In this way blood glucose
concentrations remain stable and no adverse effects have been experienced in our
studies
3.For the weight, water intake and urine output changes showed, it is better to provide
a weekly line chart which may reflect the details and fluctuations.
Response:
We have previously tried that but the figures become cluttered due to large number of
animals and the critical information would be blurred. Fluctuations in weights, water
consumptions and urine outputs do occur during treatment in response to such
situations as overnight starvation but the overall terminal changes are more critical in
conveying the intended message than piecemeal effects of interventions.
4.Please unify the markers used for indicating significance which were disordered and
confusing (&@*#^). For instance, may use # for comparing with normal control; * for
untreated diabetic group;
Response:
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Reviewer #2: The authors report the effects of 40-day daily treatment with the main
flavonoid of grapefruit, Naringin, to a cohort of SZT-injected rats as a model of Type-1
Diabetes. Control cohorts included SZT-treated and normal rats, given either water or
naringing, as well as a reference cohort of SZT-treated rats given insulin twice daily.
After the 40-day treatment the cohorts were subjected to IPGTT using 3.0 g/kg
dextrose by intraperitoneal injection. The next day the animals were sacrificed and
blood was collected for a number of measurements, including insulin, ions, and
metabolites. The authors describe the differences in ketoacidosis biomarkers between
the Naringing-treated cohorts and control rats, suggesting that this treatment may
improve ketoacidosis, which is the main message of this manuscript. The molecular
target and physiological mechanism is not understood, and this cannot be known from
exploratory in vivo experiments. However, the authors go to great lengths to
hypothesize, but this seems unnecessary and potentially the most deterring aspect of
the lengthy discussion section. The authors report and underscore a lack of significant
differences between Naringin-treated and control rats in the IPGTT experiment.
However, because of the relatively large dose of sugar used (in particular for a T1D
model) this single GTT experiment is insufficient to fully support the claim of the
authors. One further recommendation is changing the manuscript title to represent only
the positive observations, for example: “Grapefruit compound Naringin improves
ketoacidosis metabolites and lipid oxidation and in Type-1 Diabetes rat model”.
Editorial recommendation: major revisions.
Response:
We have previously reported inability of naringin to improve glucose intolerance in rats
treated with STZ after a similar glucose challenge (J Cardiovasc Pharmacol. 2012
Feb;59(2):133-41) hence our observation here is not isolated. Naringin has not be
demonstrated to be an insulin secretagogue and its proposed insulinotropic effects are
apparent only in simulated type 2 diabetes models (Diabetes Res Clin Pract. 2012
Jul;97(1):105-11). Currently available scientific evidence suggests that naringin and its
aglycone naringenin could be acting like insulin sensitizers just like metformin (Arch
Biochem Biophys. 2012 Feb 1;518(1):61-70; Biochem Biophys Res Commun. 2010 Jul
23;398(2):178-83) by activating AMPK. In this context, it is not surprising that we did
not observe improved glucose tolerance in a type 1 diabetes rat model. It cannot be
argued that 3.0 g/kg body weight glucose used in this study was too high to show
differences in IPGTT since even in non-STZ-treated rats, there were no significant
difference in glucose tolerance between naringin-treated and control rats. A lower dose
of glucose could have produced a flat curve considering the difference in blood glucose
concentrations between STZ-treated and non-STZ-treated rats.
With anticipated permission of the Editor, we have changed the title accordingly
Main comments:
1)The introduction and discussion are too long and particularly focused on ketoacidosis
as the main source of all ailments in diabetes. Major revision is required to remove
sensationalistic language, please use ONLY standard scientific language that
describes facts and credit associated literature references. To be very specific, replace
the words/sentences: “courtesy”, “exacerbate”, “catabolic nature”, “contentious issues”,
“random blood glucose”, “diabetic state”; as well as convoluted/incorrect concepts like
“pro-hyperglycemia insulin counter-regulatory hormones”, “freely producing hydrogen
ions which bind an overwhelm serum bicarbonate buffering capacity eventually leading
to metabolic acidosis”, “hyperglycemia-associated oxidative stress causes lipid
peroxidation due to increased ROS leading to overproduction of MDA”. There are also
a number of unsupported statements like “offer some hope”, “devoid of adverse
effects”, “abrogated metabolic acidosis”, “metformin-like effects” and “demonstrated
powerful antioxidant effect”. Note that “powerful” is not an objective and meaningful
word in this context (i.e. low redox potential of the molecule? binds with high affinity to
a target?).
Response:
Noted. The offensive words/phrases have been purged where appropriate and the
introduction and discussion sections shortened. However, we need to point out that the
study was designed primarily to investigate the effects of naringin on diabetic
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
ketoacidosis with glucose intolerance as a confirmation of diabetes and oxidative
stress as a possible mechanism of action. Diabetic ketoacidosis is not a source of
diabetes but rather a metabolic complication besides nephropathy, cardiomyopathy,
retinopathy and neuropathy which we were not intent on investigating in this setting.
We see no problem with using some of the phrases such as “random blood glucose”
which is clinically applicable as opposed to “fasting blood glucose”. Similarly we see
nothing wrong with referring to naringin as having ‘metformin-like effects” in the control
of blood glucose as it appears to be an emerging consensus among different
investigators in this field.
2)All instances of the sentence “Diabetic groups” (or “diabetic rats”) should be changed
to “SZT-treated group”. Similarly, “untreated diabetic group” would be substituted with
“SZT-treated control cohort”, etc.
Response:
Done
3)Figure 1 shows the BW at the end of the study, please show a longitudinal
scatterplot. Figure 4 shows only the fasting glucose on day 28 of treatment, however,
day 0 and 14 were also measured. This data should be included.
Response:
Done.
4) Fasting plasma insulin (FPI) was measured on day 42, which is 1-day post GTT on
day 41. Therefore, this protocol must have required 2 nights of fasting in a row with a
short ad libitium feeding time in between, which is not a standard recovery post-GTT.
This needs to be clarified and stated because it may possibly lead to differences with
other study designs in the future.
Response:
Fasting blood glucose were done on days 0, 14 28 and 41 but not 42 as part of IPGTT.
The error has been corrected. The animals were then sacrificed on day 42.
4)The formulas for concentrations of [AcAc] and [3HB] are not consistent with
concentration units. Please provide literature references for these methods. Please
provide a reference for the quoted extinction coefficient of 1.56x10^5 for the MDA
assay. Similarly, it would seem that the measurement of glycogen would require a
standard curve to convert the spectrophotometer measurements to mg/g liver protein.
Please include all data, literature references, and methods needed.
Response:
Anion Gap (AG) was calculated according to: Clin J Am Soc Nephrol. 2007
Jan;2(1):162-74, (reference no 11 in the revised manuscript) and expressed as mM
(mmol/L) which is also the same as mEq/L. References for MDA (S Afr J Sci
2010;106:1-5) and glycogen determination (Arch Biochem 1950;25(1):191-200) are
provided in the methods sections in the manuscript. Standard curves were used to
determine the concentrations of the unknowns in all experiments and would not add
value to the information on the figures unless provided as supplementary data.
5)The single IPGTT experiment using a 3 g/kg dose of sugar is inconclusive because
the resulting measurements ~30 mmol/L fall outside the “dynamic range” of blood
glucose homeostasis. As observed in Figure 5B, these animals lacking beta-cells
cannot effectively respond to such doses of sugar, and do not return to baseline even
after 2.5 hr. Therefore, lack of differences in this experiment are insufficient evidence to
support the negative claim. The manuscript should be modified to take into account this
possibility.
Response:
Whatever the amount of glucose administered, blood glucose concentrations never
return to baselines in GTT even after 2 hrs in diabetic individuals and this is one of the
criteria clinically used to diagnose diabetes. Fasting blood glucose concentrations in
STZ-treated rats were above 25 mM before loading glucose anyway, meaning that any
amount of glucose loaded would have spiked blood glucose levels beyond
physiological range. In non-STZ-treated rats, 3.0 g/kg did not increase blood glucose
concentrations beyond physiological ranges and there were no differences between
controls and naringin-treated groups even in the presence of insulin suggesting lack of
hypoglycemic effects of naringin in normal or low insulin concentrations. A lower dose
of glucose could have produced a flat curves considering the differences in blood
glucose concentrations between STZ-treated and non-STZ-treated rats. Hypoglycemic
effects of naringin are reported in simulated type 2 diabetes models where there is
hyperinsulinemia (Nutrients. 2013 Feb 27;5(3):637-50).
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not acronyms, of funding institutions, and
use initials to identify authors who
received the funding.
Describe the role of any sponsors or
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You must provide an ethics statement if
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specimens or tissue samples, or
vertebrate animals, embryos or tissues.
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be included in the Methods section of your
manuscript. Please write "N/A" if your
study does not require an ethics
statement.
Human Subject Research (involved
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All research involving human participants
must have been approved by the authors'
Institutional Review Board (IRB) or an
equivalent committee, and all clinical
investigation must have been conducted
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the Declaration of Helsinki. Informed
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consent was given, the reason must be
explained (e.g. the data were analyzed
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It is my pleasure to submit our original research findings on the study we conducted to 
investigate the effects of naringin, a bioflavanoid on metabolic aspects of type 1 diabetes. 
Previous studies have suggested that naringin or its aglycone, naringenin have hypoglycemic 
effects and are associated with positive outcomes in experimental diabetes animal models. 
Contrary to some of these findings, our study seems to suggest that naringin does not exhibit 
hypoglycemic effects in insulin deficiency and may therefore, like metformin require insulin 
to lower blood glucose. We further report that naringin mitigates aspects of diabetic 
ketoacidosis in type 1 diabetes. We also report that naringin relieves oxidative stress 
associated with hyperglycemia in type 1 diabetes. The impact of our study would be that 
naringing supplements may prevent complications of type 1 diabetes such as ketoacidosis 
pending further clinical studies. 
This is the first time we have submitted this manuscript to your journal and we do not have a 
preference for any academic editor, neither do we oppose any reviewers. The authors have 
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Hypoglycemic effects of grapefruit juice are well known but the effects of naringin, its main 23 
flavonoid on glucose intolerance and metabolic complications in type 1 diabetes are not known.  24 
Objectives 25 
To investigate the effects of naringin on glucose intolerance, oxidative stress and ketonemia in 26 
type 1 diabetic rats. 27 
Methods 28 
Sprague-Dawley rats divided into 5 groups (n=7) were orally treated daily with 3.0 ml/kg body 29 
weight (BW)/day of distilled water (group 1) or 50 mg/kg BW of naringin (groups 2 and 4, 30 
respectively). Groups 3, 4 and 5 were given a single intra-peritoneal injection of 60 mg/kg BW 31 
of streptozotocin to induce diabetes. Group 3 was further treated with subcutaneous insulin (4.0 32 
IU/kg BW) twice daily, respectively.  33 
Results 34 
Stretozotocin (STZ) only-treated groups exhibited hyperglycemia, polydipsia, polyuria, weight 35 
loss, glucose intolerance, low fasting plasma insulin and reduced hepatic glycogen content 36 
compared to the control group. Furthermore they had significantly elevated Malondialdehyde 37 
(MDA), acetoacetate, β-hydroxybutyrate, anion gap and significantly reduced blood pH and 38 
plasma bicarbonate compared to the control group. Naringin treatment significantly improved 39 
Fasting Plasma Insulin (FPI), hepatic glycogen content, malondialdehyde, β-hydroxybutyrate, 40 
acetoacetate, bicarbonate, blood pH and anion gap but not Fasting Blood Glucose (FBG) 41 
compared to the STZ only-treated group. 42 
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Conclusions  43 
Naringin is not hypoglycemic but ameliorates ketoacidosis and oxidative stress. Naringin 44 
supplements could therefore mitigate complications of diabetic ketoacidosis. 45 
Key words 46 
Naringin, antioxidants, ketoacidosis, hyperglycemia. 47 
INTRODUCTION 48 
Diabetes mellitus (DM) is a consequence or absolute of relative insulin deficiency leading to 49 
hyperglycemia and concomitant disturbances in carbohydrate, fat and protein metabolism [1, 50 
2].  51 
Diabetic ketoacidosis (DKA) is an acute life threatening complication of DM. It is defined by 52 
blood glucose >11 mmol/l, venous pH <7.3, and bicarbonate <15 mM, ketonemia and ketonuria 53 
[3, 4]. DKA primarily affects patients with type 1 but can also occur in type 2 diabetes under 54 
conditions of metabolic stress such as infection, trauma and surgery [5].  55 
Hyperglycemia-induced oxidative stress causes pancreatic β-cell dysfunction due to pro-56 
inflammatory cytokines which induce the release of insulin counter-regulatory hormones 57 
(glucagon, cortisol and growth hormone) leading to increased hepatic gluconeogenesis and 58 
hyperglycemia [6, 7, 8]. Increased lipolysis accelerate the delivery of free fatty acids to the 59 
liver for ketone body {acetoacetate (AcAc) and β-hydroxybutyrate (3-HB)} synthesis [7, 9]. 60 
AcAc and 3-HB are strong organic anions that dissociate freely generating increased hydrogen 61 
ions which overwhelm the normal plasma bicarbonate buffering capacity resulting in metabolic 62 
acidosis and increased anion gap (AG), (defined as the sum of serum chloride and bicarbonate 63 
concentrations subtracted from the serum sodium concentrations) [9, 10, 11].  64 
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Therapeutic management of DKA is yet to be optimised but includes adequate fluid 65 
replacement and insulin infusion to correct electrolyte imbalance and hyperglycaemia, 66 
respectively [4]. Currently, there are no clear-cut guidelines defining loss of glycemic control 67 
or propensity to hyperosmolar states (blood glucose of 33 mM or more) which may predispose 68 
vulnerable patients to DKA. However, monitoring of sodium, potassium, magnesium and 69 
phosphorus levels to maintain electrolyte balance, hemogram to assess anaemia and blood pH 70 
and gas analysis to determine ketonemia are routinely done. Contentious issues on fluid 71 
replacement therapy include the amount and type of fluids (normal saline or Ringer’s lactate) 72 
to be used and the rate of delivery [4, 12]. Routinely, normal saline is used for fluid expansion 73 
followed by intravenous insulin infusion at 0.1 U/kg/h until the patient is stabilised with 74 
dextrose to maintain euglycemia then switched to subcutaneous insulin with a dietary plan [12]. 75 
However, hospitalisation, stabilisation and subsequent follow-up pose challenges especially to 76 
patients with disadvantaged socio-economic backgrounds hence a dietary plan that mitigates 77 
the onset of DKA may be a viable cost effective patient care option. 78 
Consequently, medicinal plants which have traditionally been used to manage diabetes offer 79 
some hope as they have less side-effects commonly associated with conventional medications 80 
[9]. Naringin (4’,5,7-trihydroxy flavonone-7-rhamnoglucoside), the major flavonoid in 81 
grapefruit juices has been shown to possess pharmacological properties such as antioxidant, 82 
antidiabetic and antidyslipidemic effects [13, 14, 15, 16]. Hypoglycemic effects of naringin are 83 
well documented [17, 18] and Punithavathi et al [15] have further shown that 30 mg/kg of 84 
naringin co-administered with 50 mg/kg of vitamin C prevented oxidative stress, improved 85 
fasting plasma insulin concentrations and glucose intolerance. Hyperglycemia in a diabetic 86 
state is associated with increased oxidative stress [15, 16] which exacerbates DKA hence it is 87 
envisaged that with its demonstrated antioxidant effects, naringin could ameliorate glucose 88 
intolerance and metabolic complications associated with DKA.  89 
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Aims and objectives 90 
This study was designed to investigate the effects of naringin on glucose intolerance, metabolic 91 
benchmarks of DKA and oxidative stress in streptozotocin (STZ)-induced diabetes in rats. 92 
MATERIAL AND METHODS 93 
Chemicals and Reagents 94 
Naringin, D-glucose, STZ, citrate buffer, hydrochloric acid, sulphuric acid, potassium 95 
hydroxide, ethanol, sodium sulphate and phenol were all purchased from Sigma-Aldrich Pty. 96 
Ltd, Johannesburg, South Africa.  97 
Insulin (Novo Nordisk®, Norway), normal saline, portable glucometers and glucose test strips 98 
(Ascencia Elite™, Bayer Leverkusen, Germany) were purchased from a local pharmacy. 99 
Halothane and other accessories were provided by the Biomedical Resource Unit (BRU) of the 100 
University of KwaZulu-Natal, Durban, South Africa. 101 
Animal Treatment 102 
Male Sprague-Dawley rats of 200-300g body weight were provided by the Biomedical 103 
Resource Unit of the University of KwaZulu-Natal and divided into 5 groups (n = 7), housed 104 
seven rats per cage. Animals were given free access to standard commercial chow and drinking 105 
tap water ad libitum. The rats were maintained on a 12 hour dark-to-light cycle of 08.00 to 106 
20.00 hours light in an air controlled room (temperature 25 ±2ºC, humidity 55% ±5%) and 107 
were handled humanely, according to the guidelines of the Animal Ethics Committee of 108 
University of KwaZulu-Natal which approved the study. 109 
Type 1 DM was induced by a single intraperitoneal injection of 60 mg/kg BW of STZ dissolved 110 
in 0.2 ml citrate buffer, pH 4.5 after an overnight fast in groups 3, 4 and 5, respectively. Diabetic 111 
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status was confirmed 3 days after STZ administration by tail pricking to analyse the blood 112 
glucose levels. Animals with random blood glucose concentrations above 11.0 mmol/L were 113 
considered diabetic and were included in the study [19] and immediately commenced on 114 
treatment. 115 
Naringin (50 mg/kg BW/day in distilled water) was orally administered to groups 2 and 4 while 116 
regular insulin (4.0 IU/kg) was further administered subcutaneously twice daily to group 3. 117 
Distilled water (3.0 ml/kg BW/day) was administered to groups 1 and 5, respectively orally, 118 
(Table 1). Animal weights and water consumption were measured daily. The animals were 119 
further placed in solitary metabolic cages on day 40 of treatment and 24-hour urine samples 120 
collected measured and recorded. The animals were sacrificed by halothane overdose on day 121 
42 of treatment and blood samples collected via cardiac puncture and plasma samples stored at 122 
-80°C for further biochemical analysis.  123 
Table 1. Animal treatment protocol. The animals were weighed and randomly divided into 5 124 
groups, (n=7). Naringin and distilled water were orally administered daily. BW = per kg body 125 
weight. 126 
    Treatment 
 
Groups 






Insulin, (U/ BW 








1 3.0 - - - - 
2 - 50.0 - - - 
3 - - 4.0 - - 
4 - - - 50.0 - 
5 - - - - 3.0 
 127 
 128 
2.3 Methods 129 
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2.3.1 Blood glucose testing 130 
FBG measurements were done on treatment days 0, 14 and 28, respectively. On treatment day 131 
41, Glucose Tolerance Tests (GTT) were done after an overnight fast followed by a single 132 
intraperitoneal injection of 3.0 mg/kg BW of glucose in normal saline and blood glucose levels 133 
were measured at times 0, 15, 30, 60, 90 and 120 minutes. Insulin treatment for group 4 was 134 
withheld on the day of GTT. Blood glucose analysis was done as previously described and the 135 
calculated Area under the curve (AUC) from blood-glucose concentration-time curves 136 
presented as AUC units {(mmol/L) X Time (minutes)}. 137 
Determination of plasma insulin 138 
An ultra-sensitive rat insulin enzyme-linked immunoassay kit (DRG Diagnostics, Marburg, 139 
Germany) was used to analyse the plasma insulin levels as per the manufacturer’s instructions. 140 
The optical density was determined by a microplate reader (EZ Read 400, Biochrom®) at 450 141 
nm.  142 
Hepatic glycogen assay 143 
Hepatic glycogen content was measured by the modified method of Seifter et al.,[20]. Briefly, 144 
the liver tissue was homogenised in 1.0 ml of 30% KOH saturated with Na2SO4. The 145 
homogenate obtained was dissolved by boiling in a water bath (100˚C) for 30 minutes, vortexed 146 
and cooled on ice. Glycogen was then precipitated with 2.0 ml of 95% ethanol, vortexed, 147 
incubated on ice for 30 min and later centrifuged at 550 g for 30 min. The glycogen pellets 148 
obtained were then re-dissolved in 1.0 ml of distilled water which was thereafter treated with 149 
1.0 ml of 5% phenol and 5 ml of 96-98% sulphuric acid respectively. This was incubated on 150 
ice bath for 30 min and the absorbance measured at 490 nm using a spectrophotometer 151 
(Genesys 20, Thermo Spectronic®). Glycogen content was expressed as mg/g liver protein. 152 
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Determination of serum electrolyte and blood pH levels 153 
Serum sodium (Na⁺), potassium (K⁺), chloride (Cl⁻) and bicarbonate (HC0₃⁻) levels were 154 
analysed using an automated chemistry analyser (Beckman Coulter, Synchron LX20 Clinical 155 
Systems, California, USA) while blood pH was determined on heparinised blood using a 156 
pH/blood gas analyser (Chiron Diagnostics, Halstead, Essex, UK).  157 
The anion gap (AG) was calculated using the formula: 158 
𝐴𝐺 = {[𝑁𝑎+] + [K+]} − {[Cl−] + [HC03−] [11] 159 
Plasma thiobarbituric acid reactive substances (TBARS) assay 160 
Plasma TBARS assay was carried out according to the modified method of Phulukdaree et al 161 
[21]). Briefly, 200 µl of plasma samples were added to 500 µl of 2% phosphoric acid (H3PO4), 162 
400 μl of 7% H3PO4 and 400 µl of BHT/TBA solution in a set of clean glass test-tubes. In 163 
another set of eight clean fresh test tubes, 200 µl of serially diluted malondialdehyde (MDA) 164 
standard was added to 500 µl of 2% H3PO4, 400 μl of 7% H3PO4 and 400 µl of butylated 165 
hydroxytoluene (BHT)/ Thiobarbituric acid (TBA) solution. The reactions in both sets of tubes 166 
were initiated with 200 μl of 1.0 M HCl. All tubes were incubated in a shaking boiling water 167 
bath (100oC) for 15 minutes and cooled at room temperature. n-butanol (1.5 ml) was then added 168 
to each tube and mixed thoroughly.  Top phase (200 µl) was then transferred to a 96-well micro-169 
plate in and read at 532 and 600 nm using micro-plate reader (Spectrostar®). Plasma MDA 170 
concentrations were calculated using an extinction coefficient of 1.56x105M-1cm-1.  171 
Analysis of serum ketone body concentrations  172 
Serum and urine ketone body levels were determined by the spectrophotometric enzymatic 173 
assay kit (Enzychrom TM, BioAssay systems, EKBD-100) according to the manufacturer’s 174 
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instructions. The optical density (OD) was read at 340 nm using a spectrophotometer (Genesys 175 
20, Thermospectronic) and the concentrations calculated according to the formula: 176 
[𝐴𝑐𝐴𝑐] =
𝑂𝐷 𝑏𝑙𝑎𝑛𝑘 − 𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷 𝑤𝑎𝑡𝑒𝑟 − 𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 177 
A similar procedure was repeated for the 3-β hydroxybutyrate (3-HB) assay using the 3-HB 178 
buffer, reagent and standard, respectively and the concentrations calculated using the formula: 179 
[3𝐻𝐵] =
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒 – 𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 − 𝑂𝐷 𝑤𝑎𝑡𝑒𝑟
 180 
Statistics 181 
The data was presented as mean ± SD and analyzed by GraphPad Prism Software® Version 182 
5.0. One-Way ANOVA or Student t-tests and non-parametric Mann–Whitney tests were used 183 
where applicable to determine statistical significance. Values of P˂ 0.05 were taken to imply 184 
statistical significance. 185 
 186 
RESULTS 187 
Animal growth change during treatment period 188 
STZ only-treated groups exhibited significant (p<0.0001) weight loss compared to the normal 189 
control group. Treatment with insulin or naringin significantly (p<0.0001) increased weight 190 
gain compared to the non-treated STZ group. Treatment with naringin had no significant 191 
change in weight gain in normal rats compared to the control (Fig 1). 192 
Figure 1: Animal weight changes during treatment period. (***p<0.0001 compared to normal 193 
control, #p<0.0001 compared to non-treated STZ group). 194 
Water consumption during treatment period  195 
 
 Naringin ameliorates diabetic ketoacidosis 
10 
 
The average daily water consumption was significantly (p<0.0001) higher in untreated STZ 196 
rats compared to normal control group. However, water intake was significantly (p<0.0001) 197 
reduced in the insulin or naringin treated groups compared to the non-treated STZ group (Fig 198 
2). 199 
Fig 2. Water consumption during treatment period. (***p<0.0001 compared to normal control, 200 
#p<0.0001 compared to untreated STZ group). 201 
Urine output 202 
The urine output was significantly (p<0.0001) elevated in the untreated STZ group in 203 
comparison to the normal control group. Treatment with insulin significantly (p<0.05) reduced 204 
urine output in STZ treated animals compared to the untreated STZ group. However, naringin 205 
treatment did not have any significant effect on urine output in STZ-treated  animals compared 206 
to the untreated STZ group (Fig 3). 207 
Figure 3. 24-hour urine output collected after the animals were put in metabolic cages. 208 
(***p<0.0001 compared to normal control, # p<0.05 compared to untreated STZ group). 209 
Glucose tolerance  210 
FBG levels were significantly higher (p<0.0001) in the untreated STZ group compared to the 211 
normal control group. However, insulin but not naringin treatment significantly (p<0.05) 212 
improved the FBG levels compared to the untreated STZ group (Fig 4).  213 
Fig 4. Fasting blood glucose levels measured by tail pricking after an overnight fast. 214 
(***p<0.001 compared to the normal control group, #p<0.05 compared to untreated STZ 215 
group). 216 
The untreated STZ group showed glucose intolerance compared to the normal control (Fig 5A 217 
and B) with significantly (p<0.0001) increased calculated Area Under the Curve (AUC) further 218 
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compared to normal control group. Neither naringin nor insulin treatment significantly 219 
improved the AUCs in STZ-treated group (Figure 5C). 220 
Fig 5. Glucose Tolerance Tests (GTT) after the animals were fasted overnight and challenged 221 
with intreperitoneal injection of 3.0 g/kg BW of glucose in normal saline in normal animals 222 
treated with distilled water (controls) or naringin (A) and STZ-treated animals (B). Insulin 223 
treatment was withheld on the day of GTT and the figures were plotted in different graphs for 224 
clarity considering the large differences in blood glucose concentrations between normal and 225 
STZ groups on the y-axis. C; Calculated AUC from GTT. (***p<0.0001 compared to the 226 
normal control group). 227 
 228 
Fasting plasma insulin  229 
FPI concentration were significantly (p<0.0001) lower in the STZ-treated group compared to 230 
the normal control group. Naringin or insulin significantly (P<0.01) improved FPI 231 
concentrations in the STZ-treated compared to the untreated STZ group, respectively (Fig 6). 232 
Surprisingly, naringin treatment significantly increased FPI concentrations in normal rats 233 
compared to the controls. 234 
Fig 6. Plasma insulin concentrations after blood was collected by cardiac puncture. 235 
(***p<0.0001, ^p<0.05 compared to normal control, #p<0.05 compared to STZ only-treated 236 
animals). 237 
 238 
Hepatic glycogen levels 239 
Hepatic glycogen concentrations were significantly (p<0.0001) reduced in STZ-treated 240 
compared to the control group. Treatment with insulin or naringin significantly (p<0.05) 241 
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increased hepatic glycogen content compared to the STZ only-treated group, respectively. 242 
Naringin treatment of normal rats caused significant (p<0.05) elevation of hepatic glycogen 243 
content compared to the normal control (Fig 7). 244 
Fig 7. Glycogen levels in homogenised hepatic tissue. (***p< 0.0001, ^p< 0.05 compared to 245 
normal control, #p<0.05 compared to STZ only-treated rats, respectively) 246 
Plasma lipid peroxidation (TBARS assay)  247 
Plasma MDA concentrations in STZ only-trated group were significantly (p<0.0001) elevated 248 
compared to the normal control group. Naringin or insulin significantly (p<0.0001) reduced 249 
plasma MDA concentrations in STZ-trated rats compared to the STZ only treated group, 250 
respectively (Fig 8). 251 
Fig 8. Plasma concentrations of MDA measured as a marker for lipid peroxidation. 252 
(***p<0.001 compared to normal control, #p<0.0001 compared to STZ only-treated group). 253 
Serum β-hydroxybutyrate (3-HB) levels 254 
Serum β-hydroxybutyrate (3-HB) levels were significantly (p<0.001) elevated in the STZ only-255 
treated compared to the normal control group. Treatment with insulin or naringin significantly 256 
(p<0.05) reduced the levels of 3-HB compared to the STZ only-treated group, respectively (Fig 257 
9A).  258 
Serum acetoacetate (AcAc) levels 259 
Serum acetoacetate (AcAc) levels were significantly (p<0.0001) elevated in the STZ only-260 
teated compared to normal control group. However, naringin significantly (p<0.05) reduced 261 
plasma AcAc levels in STZ-treated compared to the STZ only-treated rats (Fig 9B). 262 
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Fig 9. A; Serum 3-β-hydroxybutyrate (3HB) levels. (***p<0.0001 compared to normal 263 
untreated control, #p<0.05 compared to STZ only-treated rats) and B; Serum acetoacetate 264 
(AcAc) levels. (***p<0.0001 compared to normal control, #p<0.05 compared to STZ only-265 
treated group) 266 
Serum electrolyte and blood pH  267 
Serum sodium, chloride and bicarbonate and blood pH were significantly (p<0.01, p<0.0001, 268 
p<0.0001 and p<0.05, respectively) reduced, while potassium was significantly (p<0.05) 269 
elevated in the STZ only-treated compared to the normal control group. Insulin significantly 270 
(p<0.05) increased sodium and reduced potassium in the STZ-treated compared to the STZ 271 
only-treated group, respectively. Naringin or insulin significantly (p<0.05) increased plasma 272 
bicarbonate and blood pH in STZ-treated compared to the STZ only-treated diabetic rats, 273 
respectively (Table 2).  274 
Table 2. Serum electrolytes and blood pH. (***p<0.0001, **p<0.01 and *p<0.05 compared to 275 






STZ-insulin STZ-Naringin STZ 
Sodium (mM) 142.70±0.56 142.80±0.37 140.00±1.00& 132.20±1.50 135.00±1.79** 
Potassium (mM) 6.42±0.30 7.120±0.59 5.87±0.12& 7.34±0.59 7.56±0.46* 
Chloride (mM) 103.80±0.89 103.00±0.63 100.30±1.33 96.20±2.40 96.40±1.36*** 
Bicarbonate (mM) 
24.77±0.76 24.74±1.04 21.18±0.69 # 17.63±0.64 @ 
13.10±0.54 
*** 
Blood pH 7.4±0.24 7.33±0.20 7.33±0.17& 7.4.00±0.31@ 6.64±0.30** 
 278 
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Anion gap (AG) 279 
Calculated AG was significantly (p<0.0001) increased in the STZ only-treated group compared 280 
to the normal control group. Naringin or insulin treatment significantly (p<0.05) decreased the 281 
serum AG in the STZ-treated groups compared to the STZ only-treated group, respectively 282 
(Fig 10). 283 
Fig 10: Anion gap (AG) calculated from serum electrolytes as previously described [11]. (***p< 284 
0.0001 compared to normal control group, #p< 0.05 compared to the STZ only-treated group). 285 
DISCUSSION 286 
This study was based on a typical type 1 diabetes model created with STZ which selectively 287 
and irreversibly completely destroys the pancreatic β-cells by oxidative damage. Interestingly, 288 
naringin treatment of normal rats was associated with relative increase in FPI concentrations 289 
(Fig 6). Considering that insulin treatment similarly increased FPI in diabetic animals, we 290 
speculate that the antioxidant effects of naringin reduced oxidative stress in the pancreatic β-291 
cell mitochondria leading to increased ATP synthesis and subsequent insulin secretion. By its 292 
anabolic effects, insulin similarly to naringin, boosted residual anti-oxidant capacity of the β-293 
cells leading to increased insulin secretion. This could have limited oxidative damage of STZ 294 
to allow the β-cells to retain some residual activity. Potential insulinotropic effects of naringin 295 
have only recently been demonstrated [22]. 296 
STZ-treated rats exhibited significant weight loss compared to controls (Fig 1). It may be 297 
argued that diabetes conferred hypophagic state since we did not measure food intake but it 298 
should also be considered that loss of body mass is a well known phenomenon in type 1 299 
diabetes irrespective of food consumption rates [3, 13, 15]. That naringin, like insulin 300 
significantly attenuated weight loss in diabetic rats further suggests that, weight loss in diabetic 301 
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rats was due to lipid and protein catabolism (associated with insulin deficiency) which were 302 
inhibited by both naringin and insulin, respectively. Hence we speculate that antioxidant effects 303 
of naringin reduced oxidative stress and free radicals which are known to provoke the release 304 
of catabolic insulin counter-regulatory hormones [9].  305 
Polydipsia and polyuria were also observed in STZ-treated animals compared to the normal 306 
control group (Fig 2 and 3). Hyperglycemia in DKA leads to increased extracellular osmolality 307 
which causes dehydration. As a compensatory mechanism, increased osmolality activates 308 
hypothalamic osmoreceptors causing the release of antidiuretic hormone (ADH) which corrects 309 
the hyperosmolar state [23]. Failure of this mechanism leads to activation of thirst leading to 310 
the increased water intake. Insulin reversed both polyuria and polydipsia in STZ-treated rats. 311 
However, naringin treatment reversed only polydipsia but not polyuria suggesting that naringin 312 
inhibited thirst activation but had no anti-diuretic effects either in the normal or STZ-treated 313 
rats.  314 
Unlike insulin, naringin improved neither FBG nor glucose intolerance in STZ-treated rats (Fig 315 
4). We previously reported that naringin does not ameliorate hyperglycemia in diabetic type 1 316 
rats [13]). This is contrary to other studies that have reported hypoglycemic effects of naringin 317 
and its aglycone naringenin to be mediated by suppression of hepatic expression of key 318 
gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-319 
phosphatase (G6Pase) [13-15, 17, 24]. We concur with these observations but opine that these 320 
studies were done in simulated type 2 diabetes models where there was insulin resistance but 321 
not absolute deficiency. That insulin treatment significantly improved fasting blood glucose 322 
and plasma insulin, respectively suggests that by its anabolic effects insulin could have 323 
promoted modest pancreatic β-cell recovery in STZ- treated animals, enhanced residual insulin 324 
secretory capacity or both (Fig 4,  5B and 6). Glucose tolerance was similar between naringin-325 
treated and control rats but calculated AUC suggested that STZ-treated rats were significantly 326 
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glucose intolerant compared to normal controls (Fig 5). GTT was conducted with 327 
intraperitoneal injections of 3.0 mg/kg body weight of glucose in normal saline and even 328 
though we could not measure concurrent plasma insulin response, our results suggest that STz-329 
treated rats were already in hyperosmolar state considering the high fasting blood glucose 330 
concentrations (Fig 4 and 5 B). Since insulin treatment was withheld during GTT, it is therefore 331 
not surprising that glucose tolerance did not improve in the insulin-treated group compared to 332 
STZ only-treated group. 333 
 Liver glycogen content was significantly reduced in STZ only-treated rats compared to 334 
controls but this was significantly reversed by either naringin or insulin treatment (Fig 7). This 335 
suggests that in the absence of insulin, glucagon and other insulin counter-regulatory hormones 336 
promoted gluconeogenesis and glycogenolysis which reduced glycogen storage in the liver in 337 
STZ-treated rats but this was inhibited by either naringin or insulin treatment. Naringin 338 
treatment of normal rats interestingly significantly increased hepatic glycogen content 339 
compared the normal controls (Fig 7). Insulin is known to activate glycogen storage by 340 
increasing expression of glycogen synthase which catalyses the rate-limiting step in glycogen 341 
synthesis [25]. Even though our study did not investigate the direct effects of naringin on 342 
hepatic expression of glycogen synthase, previous studies have shown that naringin or its 343 
aglycone naringenin suppresses PEPCK and G6Pase activities via activation of AMP-activated 344 
protein kinase (AMPK) [26, 27]. It is therefore likely that in our study, naringin failed to exert 345 
hypoglyecemic effects due to insulin deficiency and hence argue that naringin has metformin-346 
like effects.  347 
Oxidative stress causes lipid peroxidation due to increased Reactive Oxygen Species (ROS) 348 
leading to overproduction of MDA, which is used as a biomarker [28, 29]. Lipid peroxidation 349 
was significantly elevated in the STZ-treated compared to the control group but was 350 
significantly reversed by naringin treatment (Fig 8). Oxidative stress stimulates production of 351 
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pro-inflammatory cytokines which cause the release of insulin counter-regulatory hormones 352 
that are known to promote ketoacidosis [3]. Therefore, the antioxidant effects of naringin either 353 
directly or through enhancing antioxidant defence systems directly or by augmenting insulin 354 
secretion reversed ketoacidosis. This is demonstrated by the significantly reduced plasma 3-355 
HB and AcAc in diabetic rats that were treated with naringin compared to the untreated diabetic 356 
group (Fig 9A and B). Insulin significantly reduced plasma 3-HB compared to untreated 357 
diabetic animals suggesting that naringin like insulin could be having a direct inhibitory effect 358 
on hydroxymethyl glutayryl Coenzyme A (HMGCoA) synthase, which catalyses the rate-359 
limiting step in ketogenesis [9].  360 
Jung et al., [25] previously showed that naringin suppresses plasma carnitine palmitoyl-O-361 
transferase (CPT) which is involved in the transport of free fatty acids (FFA) across the 362 
mitochondrial membrane for β-oxidation and ketogenesis.  Therefore, with reduced CPT levels, 363 
there is reduced ketogenesis due to decreased supply of FFA. Increased ketogenesis observed 364 
in diabetes is associated with overproduction and accumulation of ketone bodies which are 365 
strong organic anions. These dissociate freely producing hydrogen ions which bind and 366 
overwhelm serum bicarbonate buffering capacity eventually leading to metabolic acidosis in 367 
diabetes. However, naringin significantly improved plasma bicarbonate and blood pH levels, 368 
compared to STZ only-treated group (Table 2). Subsequently acid-base imbalance marked by 369 
increased AG was significantly reversed by naringin rats compared to STZ only-treated group 370 
(Fig 10). However, unlike insulin, naringin did not correct electrolyte imbalance in diabetic 371 
animals suggesting that like with insulin treatment, fluid replacement therapy should precede 372 
naringin supplementation were it to be used clinically. These observations confirm that 373 
naringin reversed metabolic acidosis associated with DKA albeit in experimental animal 374 
model.  We recently reported antidiabetic effects of grapefruit juice in experimental animal 375 
studies [30]. Naringin is the main flavanoid in grapefruit juice and therefore it seems plausible 376 
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to infer that some of the antidiabetic effects of grapefruit juice could be attributed to naringin 377 
in addition to other as yet unidentified bioactive chemical ingredients. However, naringin on 378 
its own appears in this study to be associated with favourable metabolic end-points in type 1 379 
diabetes. There is no known toxicity of naringin both to humans or experimental laboratory 380 
animals [31, 32] and we used pharmacologically effective 50 mg/kg body of naringin [13, 33, 381 
34] owing to its poor solubility in water which was dose limiting by oral gavage. Considering 382 
the failure of known endogenous antioxidants like vitamins E and C to exert positive 383 
pharmacological effects on degenerative metabolic diseases in large scale clinical trials [32], 384 
our results presented here suggest that citrus-fruit-derived flavanoids like naringin could be 385 
viable cheaper alternatives.  386 
Conclusion. 387 
Although naringin did not improve glucose intolerance, it was associated with reversal of 388 
weight loss, improved glycogen storage and insulin secretion in diabetic rats. However, 389 
naringin abrogated metabolic acidosis suggesting a role in the management of DKA. These 390 
actions of naringin appear to be mediated in part by its powerful antioxidant affects.  Our 391 
findings therefore suggest that naringin as a nutritional supplement could be protective against 392 
ketonemia in type 1 diabetes patients and may be used as adjunct therapy pending further 393 
clinical studies.  394 
Acknowledgements: 395 






 Naringin ameliorates diabetic ketoacidosis 
19 
 
1. Sarah Wild, Gojka Roglic, Anders Green, Richard Sicree, Hilary King. Global 401 
Prevalence of Diabetes Estimates for the year 2000 and projections for 2030. Diabetes 402 
Care 2004;27(5):1047-1053. 403 
2. Alberti, KGMM and Zimmet PZ. Definition, diagnosis and classification of diabetes 404 
mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. 405 
Provisional report of a WHO Consultation. Diabetic Medicine 1998;15(7);539-553. 406 
3. Usher-Smith JA, Thompson MJ and Walter FM. Factors associated with the presence 407 
of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a 408 
systematic review. BMJ  2011;343:d4092 409 
4. Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, Lee W, et al. Diabetic 410 
ketoacidosis in children and adolescents with diabetes. Pediatric Diabetes 2009;10:118-411 
133. 412 
5. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-413 
S69. 414 
6. Murunga AN. and Owira PMO. Diabetic ketoacidosis: an overlooked child killer in 415 
sub-Saharan Africa? Tropical Medicine and International Health 2013;18(11):1357–416 
1364. 417 
7. Casteels, K. and Mathieu C. Diabetic Ketoacidosis. Reviews in Endocrine & Metabolic 418 
Disorders 2003;4(2): 159-166. 419 
8. Chiasson JL, Aris-Jilwan N, Bélanger R, Bertrand S, Beauregard H, Ekoé JM et al. 420 
Diagnosis and treatment of diabetic ketoacidosis and the hyperglycemic hyperosmolar 421 
state. CMAJ: Canadian Medical Association Journal 2003;168(7):859-866. 422 
9. McPherson P and McEneny J. The biochemistry of ketogenesis and its role in weight 423 
management, neurological disease and oxidative stress. Journal of Physiology and 424 
Biochemistry 2012;68(1):141-151. 425 
10. Vladimir S. and Sherri I. Role of beta-hydroxybutyric acid in diabetic ketoacidosis: A 426 
review. Can Vet J 2011;52:426–430. 427 
11. Kraut JA and Madias NE. Serum anion gap: its uses and limitations in clinical medicine. 428 
Clin J Am Soc Nephrol 2007;2(1): 162-74. 429 
 
 Naringin ameliorates diabetic ketoacidosis 
20 
 
12. Rewers A . Current concepts and controversies in prevention and treatment of diabetic 430 
ketoacidosis in children. Current Diabetes Reports 2012;12, 524–532. 431 
13. Xulu S. and Owira PMO. Naringin ameliorates atherogenic dyslipidemia but not 432 
hyperglycemia in rats with type 1 diabetes. J Cardiovasc Pharmacol 2012;59(2):133-433 
41. 434 
14. Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus 435 
flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of 436 
action. Adv Nutr. 2014 Jul 14;5(4):404-17 437 
15. Punithavathi VR, Anuthama R, Prince PSM. Combined treatment with naringin and 438 
vitamin C ameliorates streptozotocin-induced diabetes in male Wistar rats. Journal of 439 
Applied Toxicology 2008;28(6):806-813. 440 
16. Mahmoud AM, Ashour MB, Abdel-Moneim A, Ahmed OM. Hesperidin and naringin 441 
attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine 442 
production in high fat fed/streptozotocin-induced type 2 diabetic rats. J Diabetes 443 
Complications 2012;26(6):483-90. 444 
17. Jung UJ, Lee MK, Jeong KS, Choi MS. The Hypoglycemic effects of hesperidin and 445 
naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-446 
db/db Mice. The Journal of Nutrition 2004;134(10):2499-2503. 447 
18.  Ali MM, El Kader MA. The influence of naringin on the oxidative state of rats with 448 
streptozotocin-induced acute hyperglycaemia. Z Naturforsch C 2004;59:726–33. 449 
19. Anandh Babu, PV, Sabitha KE, Shyamaladevi CS. Green Tea Extracts Impedes 450 
Dyslipidemia and Development of Cardiac Dysfunction In Streptozotocin-Diabetic 451 
Rats Clinical and Experimental Pharmacology and Physiology 2006;33(12):1184-452 
1189. 453 
20. Seifter, S. and  Dayton S. The estimation of glycogen with the anthrone reagent. Arch 454 
Biochem 1950;25(1):191-200. 455 
21. Phulukdaree A, Moodely D, Chuturgoon AA. The Effects of Sutherlandia frutescens 456 
extracts in cultured renal proximal and distal tubule epithelial cells. S Afr J Sci 457 
2010;106:1-5. 458 
 
 Naringin ameliorates diabetic ketoacidosis 
21 
 
22. Parmar HS, Jain P, Chauhan DS, Bhinchar MK, Munjal V, Yusuf M, Choube K, Tawani 459 
A, Tiwari V, Manivannan E, Kumar A. DPP-IV inhibitory potential of naringin: an in 460 
silico, in vitro and in vivo study. Diabetes Res Clin Pract. 2012 Jul;97(1):105-11. 461 
23. Arai S, Stotts N, Puntillo K. Thirst in Critically Ill Patients: From Physiology to 462 
Sensation. Am J Crit Care 2013;22(4):328-335. 463 
24. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus flavonoids on lipid 464 
metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J 465 
Biochem Cell Biol 2006;38(7):1134-45. 466 
25. Shulman RG, Bloch G, Rothman DL. In vivo regulation of muscle glycogen synthase 467 
and the control of glycogen synthesis. Proceedings of the National Academy of 468 
Sciences 1995;92(19):8535-8542. 469 
26. Zygmunt K, Faubert B, MacNeil J, Tsiani E. Naringenin, a citrus flavonoid, increases 470 
muscle cell glucose uptake via AMPK; Biochem Biophys Res Commun 471 
2010;398(2):178-83.  472 
27. Pu P, Gao DM, Mohamed S, Chen J, Zhang J, Zhou XY et al. Naringin ameliorates 473 
metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat 474 
diet Arch Biochem Biophys 2012;518(1):61-70]. 475 
28. Fiorentino TV, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and 476 
its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des 477 
2013;19(32):5695-703. 478 
29. Niki E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors  479 
2008;34(2):171-80. 480 
30. Hayanga JA, · Ngubane SP, ·Murunga AN, Owira PMO. Grapefruit juice improves 481 
glucose intolerance in streptozotocin‑induced diabetes by suppressing hepatic 482 
gluconeogenesis. Eur J Nutr. 2016 Mar;55(2):631-8.  483 
31. Li P, Wang S, Guan X, Cen X, Hu C, Peng W, Wang Y, Su W. Six months chronic 484 
toxicological evaluation of naringin in Sprague-Dawley rats. Food Chem Toxicol. 2014 485 
Apr;66:65-75. 486 
 
 Naringin ameliorates diabetic ketoacidosis 
22 
 
32. Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus 487 
flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of 488 
action. Adv Nutr. 2014 Jul 14;5(4):404-17. 489 
33. Adebiyi OO, Adebiyi OA, Owira PM. Naringin Reverses Hepatocyte Apoptosis and 490 
Oxidative Stress Associated with HIV-1 Nucleotide Reverse Transcriptase Inhibitors-491 
Induced Metabolic Complications. Nutrients. 2015 Dec 10;7(12):10352-68. 492 
34. Adebiyi OO, Adebiyi OA, Owira PMO. Naringin mitigates cardiac hypertrophy by 493 
reducing oxidative stress and inactivating c-Jun Nuclear Kinase (JNK-1) protein in type 494 





































































































































































































































Figure 4 Click here to download Figure Fig 4.docx 
 
     A 


























    B 























    C 






























































































































































































































Figure 8 Click here to download Figure Fig 8.docx 
 












































































































































Figure 10 Click here to download Figure Fig 10.docx 
 
 Naringin ameliorates diabetic ketoacidosis 
1 
 
GRAPEFRUIT-DERIVED FLAVONOID NARINGIN DOES NOT IMPROVES 1 
KETOACIDOSIS AND LIPID PEROXIDATION IN TYPE 1 DIABETES RAT MODEL 2 
GLUCOSE INTOLERANCE BUT MITIGATES OXIDATIVE STRESS AND 3 
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Hypoglycemic effects of grapefruit juice are well known but the effects of naringin, its main 25 
flavonoid on glucose intolerance and metabolic complications in type 1 diabetes are not known.  26 
Objectives 27 
To investigate the effects of naringin on glucose intolerance, oxidative stress and ketonemia in 28 
type 1 diabetic rats. 29 
Methods 30 
Sprague-Dawley rats divided into 5 groups (n=7) were orally treated daily with 3.0 ml/kg body 31 
weight (BW) /day of distilled water (group 1) or 50 mg/kg BW of naringin (groups 2 and 4, 32 
respectively). Groups 3, 4 and 5 were given a single intra-peritoneal injection of 60 mg/kg BW 33 
of streptozotocin to induce diabetes. Group 3 was further treated with subcutaneous insulin (4.0 34 
IU/kg BW) twice daily, respectively.  35 
Results 36 
Untreated diabeticStretozotocin (STZ) only-treated groups exhibited hyperglycemia, 37 
polydipsia, polyuria, weight loss, glucose intolerance, low fasting plasma insulin and reduced 38 
hepatic glycogen content compared to the control group. The diabetic groupsFurthermore they 39 
also had significantly elevated Malondialdehyde (MDA), acetoacetate, β-hydroxybutyrate, 40 
anion gap and significantly reduced blood pH and plasma bicarbonate compared to the control 41 
group. Naringin treatment significantly improved Fasting Plasma Insulin (FPI), hepatic 42 
glycogen content, malondialdehyde, β-hydroxybutyrate , acetoacetate , bicarbonate, blood pH 43 
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and anion gap but not fasting Fasting blood Blood glucose Glucose (FBG) compared to the 44 
untreated diabSTZ only-treated etic group. 45 
Conclusions  46 
Naringin is not hypoglycemic but ameliorates ketoacidosis and oxidative stress. Naringin 47 
supplements could therefore mitigate complications of diabetic ketoacidosis. 48 
Key words 49 
Naringin, antioxidants, ketoacidosis, hyperglycemia. 50 
INTRODUCTION 51 
Diabetes mellitus (DM) is a consequence or absolute of relative insulin deficiency leading to 52 
hyperglycemia and concomitant disturbances in carbohydrate, fat and protein metabolism [1, 53 
2].  54 
Diabetic ketoacidosis (DKA) is an acute life threatening complication of DM. It is defined by 55 
blood glucose >11 mmol/l, venous pH <7.3, and bicarbonate <15 mM, ketonemia and ketonuria 56 
[3, 4]. DKA primarily affects patients with type 1 but can also occur in type 2 diabetes under 57 
conditions of metabolic stress such as infection, trauma and surgery [5].  58 
Concomitant increase in insulin counter-regulatory hormones such as glucagon, 59 
catecholamines, cortisol and growth hormone are risk factors for DKA [6]. Hyperglycemia-60 
induced oxidative stress exacerbates causes pancreatic β-cell dysfunction courtesy ofdue to 61 
pro-inflammatory cytokines which further exacerbateinduce the release of pro-hyperglycemia 62 
insulin counter-regulatory hormones  (glucagon, cortisol and growth hormone) [7]leading to 63 
increased . The catabolic nature of these hormones antagonises insulin action in the liver, 64 
adipose and skeletal tissues leading to hepatic gluconeogenesis and hyperglycemia [6, 87, 98]. 65 
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Increased lipolysis accelerate the delivery of free fatty acids to the liver for ketone body 66 
{acetoacetate (AcAc) and β-hydroxybutyrate (3-HB)} synthesis [87, 109]. AcAc and 3-HB are 67 
strong organic anions that dissociate freely generating increased hydrogen ions which 68 
overwhelm the normal plasma bicarbonate buffering capacity resulting in metabolic acidosis 69 
and increased anion gap (AG), (defined as the sum of serum chloride and bicarbonate 70 
concentrations subtracted from the serum sodium concentrations) [109, 1110, 1211].  71 
Life threatening cerebral oedema is a major complication of DKA and is the most common 72 
cause of diabetes-related deaths in children or foetal loss in pregnant diabetic patients [3, 13]. 73 
Concurrent infections, poor compliance to insulin treatment, drugs that affect carbohydrate 74 
metabolism or acute illnesses such as pancreatitis and myocardial infarction are further 75 
precipitating factors [14, 15].  76 
Consequently, medicinal plants which have traditionally been used to manage diabetes offer 77 
some hope as their consumption is no longer for nutritive purposes only but also as 78 
nutraceuticals devoid of adverse effectthey have lesss side-effects commonly associated with 79 
conventional medications [109]. Naringin (4’,5,7-trihydroxy flavonone-7-rhamnoglucoside), 80 
the major flavanoid flavonoid in grapefruit juices has been shown to possess pharmacological 81 
properties such as antioxidant, antidiabetic and antidyslipidemic effects [1713, 1814, 1915, 82 
2016]. Hypoglycemic effects of naringin are well documented [2117, 2218] and Punithavathi 83 
et al [1915] have further shown that 30 mg/kg of naringin co-administered with 50 mg/kg of 84 
vitamin C prevented oxidative stress, improved fasting plasma insulin concentrations and 85 
glucose intolerance. Hyperglycemia in a diabetic state is associated with increased oxidative 86 
stress [1915, 2016] which exacerbates DKA hence it is envisaged that with its demonstrated 87 
powerful antioxidant effects, naringin could ameliorate glucose intolerance and metabolic 88 
complications associated with DKA.  89 
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Aims and objectives 90 
This study was designed to investigate the effects of naringin on glucose intolerance, metabolic 91 
benchmarks of DKA and oxidative stress in streptozotocin (STZ)-induced diabetes in rats. 92 
MATERIAL AND METHODS 93 
Chemicals and Reagents 94 
Naringin, D-glucose, STZ, citrate buffer, hydrochloric acid, sulphuric acid, potassium 95 
hydroxide, ethanol, sodium sulphate and phenol were all purchased from Sigma-Aldrich Pty. 96 
Ltd, Johannesburg, South Africa.  97 
Insulin (Novo Nordisk®, Norway), normal saline, portable glucometers and glucose test strips 98 
(Ascencia Elite™, Bayer Leverkusen, Germany) were purchased from a local pharmacy. 99 
Halothane and other accessories were provided by the Biomedical Resource Unit (BRU) of the 100 
University of KwaZulu-Natal, Durban, South Africa. 101 
Animal Treatment 102 
Male Sprague-Dawley rats of 200-300g body weight were provided by the Biomedical 103 
Resource Unit of the University of KwaZulu-Natal and divided into 5 groups (n = 7) and , 104 
housed seven rats per cage. Animals were given free access to standard commercial chow and 105 
drinking tap water ad libitum. The rats were maintained on a 12 hour dark-to-light cycle of 106 
08.00 to 20.00 hours light in an air controlled room (temperature 25 ±2ºC, humidity 55% ±5%) 107 
and were handled humanely, according to the guidelines of the Animal Ethics Committee of 108 
University of KwaZulu-Natal which approved the study. 109 
Type 1 DM was induced by a single intraperitoneal injection of 60 mg/kg BW of STZ dissolved 110 
in 0.2 ml citrate buffer, pH 4.5 after an overnight fast in groups 3, 4 and 5, respectively. Diabetic 111 
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status was confirmed 3 days after STZ administration by tail pricking to analyse the blood 112 
glucose levels. Animals with random blood glucose concentrations above 11.0 mmol/L were 113 
considered diabetic and were included in the study [2319] and immediately commenced on 114 
treatment. 115 
Naringin (50 mg/kg BW/day in distilled water) was orally administered to groups 2 and 4 while 116 
regular insulin (4.0 IU/kg) was further administered subcutaneously twice daily to group 3. 117 
Distilled water (3.0 ml/kg BW/day) was administered to groups 1 and 5, respectively orally, 118 
(Table I). Animal weights and water consumption were measured daily. The animals were 119 
further placed in solitary metabolic cages on day 40 of treatment and 24-hour urine samples 120 
collected measured and recorded. The animals were sacrificed by halothane overdose on day 121 
42 of treatment and blood samples collected via cardiac puncture and plasma samples stored at 122 
-80°C for further biochemical analysis.  123 
Table 1. Animal treatment protocol. The animals were weighed and randomly divided into 5 124 
groups, (n=7). Naringin and distilled water were orally administered daily. BW = per kg body 125 
weight. 126 
    Treatment 
 
Groups 






Insulin, (U/ BW 








1 3.0 - - - - 
2 - 50.0 - - - 
3 - - 4.0 - - 
4 - - - 50.0 - 
5 - - - - 3.0 
 127 
 128 
2.3 Methods 129 
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2.3.1 Blood glucose testing 130 
FBG measurements were done on treatment days 0, 14 and 28, respectively. On treatment day 131 
41, Glucose Tolerance Tests (GTT) were done after an overnight fast followed by a single 132 
intraperitoneal injection of 3.0 mg/kg BW of glucose in normal saline and blood glucose levels 133 
were measured at times 0, 15, 30, 60, 90 and 120 minutes. Insulin treatment for group 4 was 134 
withheld on the day of GTT. Blood glucose analysis was done as previously described and the 135 
calculated Area under the curve (AUC) from blood-glucose concentration-time curves 136 
presented as AUC units {(mmol/L) X Time (minutes)}. 137 
Determination of plasma insulin 138 
An ultra-sensitive rat insulin enzyme-linked immunoassay kit (DRG Diagnostics, Marburg, 139 
Germany) was used to analyse the plasma insulin levels as per the manufacturer’s instructions. 140 
The optical density was determined by a microplate reader (EZ Read 400, Biochrom®) at 450 141 
nm.  142 
Hepatic glycogen assay 143 
Hepatic glycogen content was measured by the modified method of Seifter et al.,[2420]. 144 
Briefly, the liver tissue was homogenised in 1.0 ml of 30% KOH saturated with Na2SO4. The 145 
homogenate obtained was dissolved by boiling in a water bath (100˚C) for 30 minutes, vortexed 146 
and cooled on ice. Glycogen was then precipitated with 2.0 ml of 95% ethanol, vortexed, 147 
incubated on ice for 30 min and later centrifuged at 550 g for 30 min. The glycogen pellets 148 
obtained were then re-dissolved in 1.0 ml of distilled water which was thereafter treated with 149 
1.0 ml of 5% phenol and 5 ml of 96-98% sulphuric acid respectively. This was incubated on 150 
ice bath for 30 min and the absorbance measured at 490 nm using a spectrophotometer 151 
(Genesys 20, Thermo Spectronic®). Glycogen content was expressed as mg/g liver protein. 152 
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Determination of serum electrolyte and blood pH levels 153 
Serum sodium (Na⁺), potassium (K⁺), chloride (Cl⁻) and bicarbonate (HC0₃⁻) levels were 154 
analysed using an automated chemistry analyser (Beckman Coulter, Synchron LX20 Clinical 155 
Systems, California, USA) while blood pH was determined on heparinised blood using a 156 
pH/blood gas analyser (Chiron Diagnostics, Halstead, Essex, UK).  157 
The anion gap (AG) was calculated using the formula: 158 
𝐴𝐺 = {[𝑁𝑎+] + [K+]} − {[Cl−] + [HC03−] [1211] 159 
Plasma thiobarbituric acid reactive substances (TBARS) assay 160 
Plasma TBARS assay was carried out according to the modified method of Phulukdaree et al 161 
[2521]). Briefly, 200 µl of plasma samples were added to 500 µl of 2% phosphoric acid 162 
(H3PO4), 400 μl of 7% H3PO4 and 400 µl of BHT/TBA solution in a set of clean glass test-163 
tubes. In another set of eight clean fresh test tubes, 200 µl of serially diluted malondialdehyde 164 
(MDA) standard was added to 500 µl of 2% H3PO4, 400 μl of 7% H3PO4 and 400 µl of butylated 165 
hydroxytoluene (BHT)/ Thiobarbituric acid (TBA) solution. The reactions in both sets of tubes 166 
were initiated with 200 μl of 1.0 M HCl. All tubes were incubated in a shaking boiling water 167 
bath (100oC) for 15 minutes and cooled at room temperature. n-butanol (1.5 ml) was then added 168 
to each tube and mixed thoroughly.  Top phase (200 µl) was then transferred to a 96-well micro-169 
plate in and read at 532 and 600 nm using micro-plate reader (Spectrostar®). Plasma MDA 170 
concentrations were calculated using an extinction coefficient of 1.56x105M-1cm-1.  171 
Analysis of serum ketone body concentrations  172 
Serum and urine ketone body levels were determined by the spectrophotometric enzymatic 173 
assay kit (Enzychrom TM, BioAssay systems, EKBD-100) according to the manufacturer’s 174 
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instructions. The optical density (OD) was read at 340 nm using a spectrophotometer (Genesys 175 
20, Thermospectronic) and the concentrations calculated according to the formula: 176 
[𝐴𝑐𝐴𝑐] =
𝑂𝐷 𝑏𝑙𝑎𝑛𝑘 − 𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒
𝑂𝐷 𝑤𝑎𝑡𝑒𝑟 − 𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 177 
A similar procedure was repeated for the 3-β hydroxybutyrate (3-HB) assay using the 3-HB 178 
buffer, reagent and standard, respectively and the concentrations calculated using the formula: 179 
[3𝐻𝐵] =
𝑂𝐷 𝑠𝑎𝑚𝑝𝑙𝑒 – 𝑂𝐷 𝑏𝑙𝑎𝑛𝑘
𝑂𝐷 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 − 𝑂𝐷 𝑤𝑎𝑡𝑒𝑟
 180 
Statistics 181 
The data was presented as mean ± SD and analyzed by GraphPad Prism Software® Version 182 
5.0. One-Way ANOVA or Student t-tests and non-parametric Mann–Whitney tests were used 183 
where applicable to determine statistical significance. Values of P˂ 0.05 were taken to imply 184 
statistical significance. 185 
 186 
RESULTS 187 
Animal growth change during treatment period 188 
Diabetic STZ only-treated groups exhibited significant (p<0.0001) weight loss compared to the 189 
normal control group. Treatment with insulin or naringin significantly (p<0.0001) increased 190 
weight gain compared to the non-treated diabetic STZ group. Treatment of the normal non 191 
diabetic rats with with naringin had no significant change in weight gain in normal rats  192 
comparison ed to the normal control (Figure 1). 193 
Figure 1: Animal weight changes during treatment period. (***p<0.0001 compared to normal 194 
control, #p<0.0001 compared to diabetic controlnon-treated STZ group.). 195 
Water consumption during treatment period  196 
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The average daily water consumption was significantly (p<0.0001) higher in untreated diabetic 197 
rats compared to normal control group. However, water intake was significantly (p<0.0001) 198 
reduced in the insulin or naringin treated groups compared to the non-treated diabeticSTZ 199 
(Figure 2). 200 
Figure 2: Water consumption during treatment period. (***p<0.0001 compared to normal 201 
control, #p<0.0001 compared to diabetic untreated STZ groupcontrol.). 202 
Urine output 203 
The urine output was significantly (p<0.0001) elevated in the untreated diabetic STZrat group 204 
in comparison to the normal control group. Treatment of the diabetic group with insulin 205 
significantly (p<0.05) reduced urine output in STZ treated animals compared to the diabetic 206 
untreated STZcontrol  group. However, naringin treatment did not have any significant effect 207 
on urine output in diabetic STZ-treated  animals compared to the untreated diabetic STZ 208 
grouprats (Figure 3). 209 
Figure 3: 24-hour urine output collected after the animals were put in metabolic cages. 210 
(***p<0.0001 compared to normal control, # p<0.05 compared to diabetic controluntreated 211 
STZ group.). 212 
Glucose tolerance  213 
Fasting blood glucose (FBG) levels were significantly higher (p<0.0001) in the diabetic 214 
untreated STZ group compared to the normal control group. However, insulin but not naringin 215 
treatment significantly (p<0.05) improved the FBG levels compared to the diabetic untreated 216 
STZ group (Fig 4).  217 
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Figure 4: Fasting blood glucose levels measured by tail pricking after an overnight fast. 218 
(***p<0.001 compared to the normal control group, @#p<0.05 compared to diabetic 219 
controluntreated STZ group.). 220 
The diabetic untreated STZ groups showed glucose intolerance compared to the normal control 221 
(Fig 5A & B) with significantly (p<0.0001) increased. C calculated area Area under Under the 222 
curve Curve (AUC) further showed that the AUCs of the diabetic groups were significantly 223 
(p<0.0001) increased compared to normal control group. N but neither naringin nor insulin 224 
treatment significantly improved the AUCs in diabetic  STZ-treated groups (Figure 5C). 225 
Figure 5: Glucose Tolerance Tests (GTT) after the animals were fasted overnight and 226 
challenged with intreperitoneal injection of 3.0 g/kg BW of glucose in normal saline in non-227 
diabeticnormal animals treated with distilled water (controls) or naringin (A) and diabetic STZ-228 
(B). Insulin treatment was withheld on the day of GTT and the figures were plotted in different 229 
graphs for clarity considering the large differences in blood glucose concentrations between 230 
normal and diabetic STZ groups on the y-axis. C; Calculated AUC from GTT. (***p<0.0001 231 
to the normal control group). 232 
 233 
Fasting plasma insulin  234 
FPI concentration wasere significantly (p<0.0001) lower in the diabetic controlSTZ-treated 235 
group compared to the normal control group. Treatment of diabetic groups with either 236 
nNaringin or insulin significantly (P<0.01) improved FPI concentrations in the STZ-treated 237 
compared to the untreated diabetic STZ controlgroup, respectively (Figure 6). Surprisingly, 238 
naringin treatment significantly increased FPI concentrations in non-diabeticnormal rats 239 
compared to the controls. 240 
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Figure 6: Plasma insulin concentrations after blood was collected by cardiac puncture. 241 
(***p<0.0001, ̂ p<0.05 compared to normal control, #p<0.05 compared to diabetic controlSTZ 242 
animals). 243 
 244 
Hepatic glycogen levels 245 
Hepatic glycogen concentrations were significantly (p<0.0001) reduced in the diabeticSTZ-246 
treated group compared to the control group. Treatment with insulin or naringin significantly 247 
(p<0.05) increased hepatic glycogen content compared to the untreated diabetic controlSTZ 248 
only-treated group, respectively. Naringin treatment of normal rats caused significant (p<0.05) 249 
elevation of hepatic glycogen content compared to the normal control (Figure 7). 250 
Figure 7: Glycogen levels in homogenised hepatic tissue. (***p< 0.0001, ^p< 0.05 compared 251 
to normal control, #p< 0.01, @ p<0.05 compared to untreated diabeticSTZ only-treated rats, 252 
respectively) 253 
 254 
Plasma MDA concentrations in diabetic controlSTZ only-trated group were significantly 255 
(p<0.0001) elevated compared to the normal control group. Naringin or insulin significantly 256 
(p<0.0001) reduced plasma MDA concentrations in diabetic STZ-trated rats compared to the 257 
diabetic controlSTZ only treated group, respectively (Figure 8). 258 
Figure 8: Plasma concentrations of Malondialdehyde MDA measured as a marker for lipid 259 
peroxidation. (***p<0.001 compared to normal control, #p<0.0001 compared to untreated 260 
diabeticSTZ only-teated group). 261 
 262 
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Serum β-hydroxybutyrate (3-HB) levels were significantly (p<0.001) elevated in the diabetic 263 
treated compared to the normal control group. Treatment with insulin or naringin significantly 264 
(p<0.05) reduced the levels of 3-HB compared to the untreated diabeticSTZ only-treated group, 265 
(Figure 9A).  266 
Serum acetoacetate (AcAc) levels 267 
Serum acetoacetate (AcAc) levels were significantly (p<0.0001) elevated in the diabetic 268 
controlSTZ only-teated compared to normal control group. However, naringin significantly 269 
(p<0.05) reduced plasma AcAc levels in diabetic STZ-treated rats compared to the diabetic 270 
controlSTZ only-treated rats (Figure 9B). 271 
Figure 9: A; Serum 3-β-hydroxybutyrate (3HB) levels. (***p<0.0001 compared to normal 272 
untreated control, #p<0.01 and @p<0.05 compared to untreated diabeticSTZ only-treated rats) 273 
acetoacetate (AcAc) levels. (***p<0.0001 compared to normal untreated control, #p<0.05 274 
untreated diabeticSTZ only-treated group) 275 
 276 
Serum sodium, chloride and bicarbonate and blood pH were significantly (p<0.01, p<0.0001, 277 
p<0.0001 and p<0.05, respectively) reduced, while potassium was significantly (p<0.05) 278 
elevated in the diabetic STZ only-treated compared to the normal control group. Treatment of 279 
the diabetic groups with iInsulin significantly (p<0.05) increased sodium and reduced 280 
potassium in the STZ-treated compared to the untreated diabetic controthe STZ only-treatedl 281 
group, respectively. Naringin or insulin treatment of diabetic rats significantly (p<0.05) 282 
increased plasma bicarbonate and blood pH in STZ-treated compared to the nonSTZ only-283 
treated diabetic rats, respectively (Table II).  284 
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Table 2. Serum electrolytes and blood pH. (***p<0.0001, **p<0.01 and *p<0.05 compared to 285 
the normal control group, #p<0.0001, @p<0.01 and &p<0.05 compared to untreated diabeticthe 286 











Sodium (mM) 142.70±0.56 142.80±0.37 140.00±1.00& 132.20±1.50 135.00±1.79** 
Potassium (mM) 6.42±0.30 7.120±0.59 5.87±0.12& 7.34±0.59 7.56±0.46* 
Chloride (mM) 103.80±0.89 103.00±0.63 100.30±1.33 96.20±2.40 96.40±1.36*** 
Bicarbonate (mM) 
24.77±0.76 24.74±1.04 21.18±0.69 # 17.63±0.64 @ 
13.10±0.54 
*** 
Blood pH 7.4±0.24 7.33±0.20 7.33±0.17& 7.4.00±0.31@ 6.64±0.30** 
 288 
 289 
Anion gap (AG) 290 
Calculated AG was significantly (p<0.0001) increased in the diabetic STZ only-treated group 291 
compared to the normal control group. Naringin or insulin treatment significantly (p<0.05) 292 
decreased the serum AG in the diabetic STZ-treated groups compared to the untreated 293 
diabeticSTZ only-treated group, respectively (Figure 10). 294 
Figure 10: Anion gap (AG) calculated from serum electrolytes as previously described [1211]. 295 
(#p< 0.0001 compared to normal control group, *p< 0.05 compared to the untreated 296 
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This study was based on a typical type 1 diabetes model created with STZ which selectively 301 
and irreversibly completely destroys the pancreatic β-cells by oxidative damage. Interestingly, 302 
treatment of both normal and diabetic rats with naringin treatment of normal rats was associated 303 
with relative increase in FPI concentrations (Fig 6) yet naringin is not known to be 304 
insulinotropic. Considering that insulin treatment similarly increased FPI in diabetic animals, 305 
we speculate that the antioxidant effects of naringin reduced oxidative stress in the pancreatic 306 
β-cell mitochondria leading to increased ATP synthesis and subsequent insulin secretion. By 307 
its anabolic effects, insulin similarly to naringin, boosted residual anti-oxidant capacity of the 308 
β-cells leading to increased insulin secretion. This could have limited oxidative damage of STZ 309 
to allow the β-cells to retain some residual activity. Potential insulinotropic effects of naringin 310 
have only recently been demonstrated [22]. 311 
Diabetic STZ-treated rats exhibited significant weight loss compared to controls (Fig 1). It may 312 
be argued that diabetes conferred hypophagic state since we did not measure food intake but it 313 
should also be considered that loss of body mass is a well known phenomenon in type 1 314 
diabetes irrespective of food consumption rates [3, 1713, 1915]. That naringin, like insulin 315 
significantly attenuated weight loss in diabetic rats further suggests that, weight loss in diabetic 316 
rats was due to lipid and protein catabolism (associated with insulin deficiency) which was 317 
were inhibited by both naringin and insulin, respectively. Hence we speculate that antioxidant 318 
effects of naringin reduced oxidative stress and free radicals which are known to provoke the 319 
release of catabolic insulin counter-regulatory hormones [109].  320 
Polydipsia and polyuria were also observed in diabetic STZ-treated animals compared to the 321 
normal control group (Fig 2 and 3). Hyperglycemia in DKA leads to increased extracellular 322 
osmolality which draws fluid from the intracellular compartment which is then lost through 323 
renal diuresis causingcauses dehydration. As a compensatory mechanism, increased osmolality 324 
activates hypothalamic osmoreceptors causing the release of antidiuretic hormone (ADH) 325 
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which corrects the hyperosmolar state [2623]). Failure of this mechanism leads to activation of 326 
thirst leading to the increased water intake. Insulin treatment of the diabetic rats reversed both 327 
polyuria and polydipsia in STZ-treated rats. However, naringin treatment reversed only 328 
polydipsia but not polyuria suggesting that naringin inhibited thirst activation but had no anti-329 
diuretic effects either in the normal or diabetic STZ-treated rats.  330 
Unlike insulin, treatment of the diabetic rats with naringin improved neither FBG nor glucose 331 
intolerance in diabetic STZ-treated rats (Fig 4). We previously reported that naringin does not 332 
ameliorate hyperglycemia in diabetic type 1 rats [1713]). This is contrary to other studies that 333 
have reported hypoglycemic effects of naringin and its aglycone naringenin to be mediated by 334 
suppression of hepatic expression of key gluconeogenic enzymes, phosphoenolpyruvate 335 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) [1713-1915, 2117, 2724]). We 336 
concur with these observations but opine that these studies were done in simulated type 2 337 
diabetes models where there was insulin resistance but not absolute deficiency. That insulin 338 
treatment significantly improved fasting blood glucose and plasma insulin, respectively 339 
suggests that by its anabolic effects insulin could have promoted modest pancreatic β-cell 340 
recovery in STZ- treated animals, enhanced residual insulin secretory capacity or both (Fig 4,  341 
5B and 6). Glucose tolerance was similar between naringin-treated and control rats but 342 
calculated AUC suggested that diabetic STZ-treated rats were significantly glucose intolerant 343 
compared to normal controls (Fig 5). GTT was conducted with intraperitoneal injections of 3.0 344 
mg/kg body weight of glucose in normal saline and even though we could not measure 345 
concurrent plasma insulin response, our results suggest that diabetic STz-treated rats were 346 
already in hyperosmolar state considering the high fasting blood glucose concentrations (Fig 4 347 
and 5 B). Since insulin treatment was withheld during GTT, it is therefore not surprising that 348 
glucose tolerance did not improve in the insulin-treated group compared to non-treated 349 
diabeticSTZ only-treated group. 350 
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 Liver glycogen content was significantly reduced in non-treated diabeticSTZ only-treated rats 351 
controls but this was significantly reversed by either naringin or insulin treatment of diabetic 352 
suggests that in the absence of insulin, glucagon and other insulin counter-regulatory hormones 353 
promoted gluconeogenesis and glycogenolysis which reduced glycogen storage in the liver in 354 
diabeticSTZ-treated rats but this was inhibited by either naringin or insulin treatment. Naringin 355 
treatment of normal rats interestingly significantly increased hepatic glycogen content 356 
compared the normal controls (Fig 7). Insulin is known to activate glycogen storage by 357 
increasing expression of glycogen synthase which catalyses the rate-limiting step in glycogen 358 
synthesis [2825]. Even though our study did not investigate the direct effects of naringin on 359 
hepatic expression of glycogen synthase, previous studies have shown that naringin or its 360 
aglycone naringenin suppresses PEPCK and G6Pase activities via activation of AMP-activated 361 
protein kinase (AMPK) [(2926, 3027]. It is therefore likely that in our study, naringin failed to 362 
hypoglyecemic effects due to insulin deficiency and hence argue that naringin has metformin-363 
like effects.  364 
Hyperglycemia-associated oOxidative stress causes lipid peroxidation due to increased 365 
Reactive Oxygen Species (ROS) leading to overproduction of MDA, which is used as a 366 
biomarker [3128, 3229]. Lipid peroxidation was significantly elevated in the diabetic STZ-367 
treated compared to the control group but was significantly reversed by naringin treatment 368 
(Figure 8). Oxidative stress stimulates production of pro-inflammatory cytokines which 369 
provoke cause the release of insulin counter-regulatory hormones that are known to provoke 370 
promote ketoacidosis [3]. Therefore, the antioxidant effects of naringin either directly or 371 
through enhancing antioxidant defence systems directly or by augmenting insulin secretion 372 
reversed ketoacidosis. This is demonstrated by the significantly reduced plasma 3-HB and 373 
AcAc in diabetic rats that were treated with naringin compared to the untreated diabetic group 374 
(Fig 9 A and B). Insulin significantly reduced plasma 3-HB compared to untreated diabetic 375 
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animals suggesting that naringin like insulin could be having a direct inhibitory effect on 376 
hydroxymethyl glutayryl Coenzyme A (HMGCoA) synthase, which catalyses the rate-limiting 377 
step in ketogenesis [109].  378 
Jung et al., [2825] previously showed that naringin suppresses plasma carnitine palmitoyl-O-379 
transferase (CPT) which is involved in the transport of free fatty acids (FFA) across the 380 
mitochondrial membrane for β-oxidation and ketogenesis.  Therefore, with reduced CPT levels, 381 
there is reduced ketogenesis due to decreased supply of FFA. Increased ketogenesis observed 382 
in diabetes is associated with overproduction and accumulation of ketone bodies which are 383 
strong organic anions. These dissociate freely producing hydrogen ions which bind and 384 
overwhelm serum bicarbonate buffering capacity eventually leading to metabolic acidosis in 385 
diabetes. However, treatment of the diabetic rats with naringin significantly improved plasma 386 
bicarbonate and blood pH levels, (Table 2) compared to untreated diabeticSTZ only-treated 387 
group (Table 2). Subsequently acid-base imbalance marked by increased AG was significantly 388 
reversed by naringin treatment of diabetic rats compared to the nonSTZ only-treated ones group 389 
(Fig 10). However, unlike insulin, naringin did not correct electrolyte imbalance in diabetic 390 
animals suggesting that like with insulin treatment, fluid replacement therapy should precede 391 
naringin supplementation were it to be used clinically. These observations confirm that 392 
naringin reversed metabolic acidosis associated with DKA albeit in experimental animal 393 
model.  We recently reported antidiabetic effects of grapefruit juice in experimental animal 394 
studies [3330]. Naringin is the main flavanoid in grapefruit juice and therefore it seems 395 
plausible to infer that some of the antidiabetic effects of grapefruit juice could be attributed to 396 
naringin in addition to other as yet unidentified bioactive chemical ingredients. However, 397 
naringin on its own appears in this study to be associated with favourable metabolic end-points 398 
in type 1 diabetes. There is no known toxicity of naringin both to humans or experimental 399 
laboratory animals [3431, 3532] and we used pharmacologically effective 50 mg/kg body of 400 
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naringin [1713, 3633, 3734] owing to its poor solubility in water which was dose limiting by 401 
gavage. Considering the failure of known endogenous antioxidants like vitamins E and C to 402 
exert positive pharmacological effects on degenerative metabolic diseases in large scale clinical 403 
trials [3532], our results presented here suggest that citrus-fruit-derived flavanoids like naringin 404 
could be viable cheaper alternatives.  405 
Conclusion. 406 
Although naringin did not improve glucose intolerance, it was associated with reversal of 407 
weight loss, improved glycogen storage and insulin secretion in diabetic rats. However, 408 
naringin abrogated metabolic acidosis suggesting a role in the management of DKA. These 409 
actions of naringin appear to be mediated in part by its powerful antioxidant affects.  Our 410 
findings therefore suggest that naringin as a nutritional supplement could be protective against 411 
ketonemia in type 1 diabetes patients and may be used as adjunct therapy pending further 412 
clinical studies.  413 
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5. Review Comments to the Author 
 
Please use the space provided to explain your answers to the questions above. You may also 
include additional comments for the author, including concerns about dual publication, 
research ethics, or publication ethics. (Please upload your review as an attachment if it 
exceeds 20,000 characters) 
 
Reviewer #1: The present study reported Narigin may improve the oxidative stress and 
ketoacidosis but have no effect on glucose tolerance in type 1 diabetic rat, which is 
interesting and challenging. There are still some concerns need to be addressed. 
1. In the current study, hypoglycemic effect of Naringin was not observed which was 
inconsistent with other reports. More discusses are needed to interpret the increased 
insulin and hepatic glycogen but no influence on glucose by Naringin treatment. 
Would the potential hypoglycemic effect of Naringin exert on mild condition? Mild 
diabetic rats are suggested to use as an additional group (e.g.STZ 35 mg/kg). Have the 
authors try to confirm its insulinotropic effect on cell lines? Or other pathways for 
example, stimulating the secretion of incretin when oral GTT performed? (J 
endocrinology, 2013,217:185-196) 
Response:  
As highlighted in our discussion, hypoglycemic effects of naringin so far demonstrated 
are apparent in type 2 diabetes rat models where there is some residual insulin secretion. 
We have previously shown that without insulin, naringin does not exert hypoglycemic 
effects {J Cardiovasc Pharmacol. 2012 Feb;59(2):133-41; Accepted Manuscript in PLOS 
ONE (PONE-D-15-28866R2)}. Enhanced insulin secretion in normal non-diabetic rats 
treated with insulin could be attributed to antioxidant potential of naringin that reduces 
reactive oxygen species concentrations in the pancreatic β-cells leading to increased ATP 
production and insulin secretion (our as yet unpublished work on the effects of naringin 
on insulin secretion in RIN-5F cell lines). Insulinotropic effects of naringin have not 
previously been fully investigated but is a possibility. DPP-IV inhibitory potential of 
naringin has recently been described (Diabetes Res Clin Pract. 2012 Jul;97(1):105-11) 
suggesting that naringin could have increased insulin secretion in these rats by increased 
GLP-1 half-life. However, enhanced insulin secretion was an unexpected finding that was 
beyond the scope of our study in the interim. 
Similarly, we unexpectedly found that naringin significantly increased glycogen content 
in non-diabetic rats compared to controls. However, this is not surprising considering our 
recent finding (Eur J Nutr. 2016 Mar;55(2):631-638) that grapefruit juice  significantly 
increases hepatic glycogen content in non-diabetic and diabetic compared to controls and 
diabetic rats, respectively by activating glucokinase and down-regulating hepatic 
activities of key gluconeogenic enzymes, PEPCK and G-6-Pase. Interestingly, insulin 
treatment of diabetic rats did not significantly increase glycogen concentrations 
compared to untreated diabetic rats. Naringin is the predominant bioflavonoid in the 
grapefruit juice and we are convinced that in the previous and present study, it activated 
Response to Reviewers
glycogen synthase via AMPK upregulation like metformin (Arch Biochem Biophys. 2012 
Feb 1;518(1):61-70). These points have been incorporated into the discussion in the 
present manuscript. 
2. STZ treatment may take some days to exert effects stably (generally 5-7 days). Why 
the authors confirm the blood glucose on day 3 after STZ treatment? Similarly, 
treatments were performed immediately following the confirmation. STZ induced 
diabetic model may lead to wide variations in weight and FBG. Some rats may 
display very severe symptom (e.g. FBG > 18 mmol/L, weight <180 g) following the 
STZ treatment. How did authors deal with this? Details of grouping are needed. 
Response:  
We have been consulted by other research groups on how we manage to induce stable 
hyperglycemia within 24 hrs of administering STZ without animal deaths. In our 
experience, the animals have to be fasted overnight, and STZ dissolved in 0.2 ml of 0.1 
M citrate buffer, pH 4.5.  It is critical that be buffer be made a fresh and the pH kept at 
4.5 without adjusting with either NaOH or NaCl. In this way blood glucose 
concentrations remain stable and no adverse effects have been experienced in our 
studies 
3. For the weight, water intake and urine output changes showed, it is better to provide a 
weekly line chart which may reflect the details and fluctuations. 
Response: 
We have previously tried that but the figures become cluttered due to large number of 
animals and the critical information would be blurred. Fluctuations in weights, water 
consumptions and urine outputs do occur during treatment in response to such 
situations as overnight starvation but the overall terminal changes are more critical in 
conveying the intended message than piecemeal effects of interventions. 
4. Please unify the markers used for indicating significance which were disordered and 
confusing (&@*#^). For instance, may use # for comparing with normal control; * for 
untreated diabetic group; 
Response: 
Done 




Reviewer #2: The authors report the effects of 40-day daily treatment with the main flavonoid 
of grapefruit, Naringin, to a cohort of SZT-injected rats as a model of Type-1 Diabetes. 
Control cohorts included SZT-treated and normal rats, given either water or naringing, as 
well as a reference cohort of SZT-treated rats given insulin twice daily. After the 40-day 
treatment the cohorts were subjected to IPGTT using 3.0 g/kg dextrose by intraperitoneal 
injection. The next day the animals were sacrificed and blood was collected for a number of 
measurements, including insulin, ions, and metabolites. The authors describe the differences 
in ketoacidosis biomarkers between the Naringing-treated cohorts and control rats, suggesting 
that this treatment may improve ketoacidosis, which is the main message of this manuscript. 
The molecular target and physiological mechanism is not understood, and this cannot be 
known from exploratory in vivo experiments. However, the authors go to great lengths to 
hypothesize, but this seems unnecessary and potentially the most deterring aspect of the 
lengthy discussion section. The authors report and underscore a lack of significant differences 
between Naringin-treated and control rats in the IPGTT experiment. However, because of the 
relatively large dose of sugar used (in particular for a T1D model) this single GTT 
experiment is insufficient to fully support the claim of the authors. One further 
recommendation is changing the manuscript title to represent only the positive observations, 
for example: “Grapefruit compound Naringin improves ketoacidosis metabolites and lipid 
oxidation and in Type-1 Diabetes rat model”. Editorial recommendation: major revisions. 
Response: 
We have previously reported inability of naringin to improve glucose intolerance in rats 
treated with STZ after a similar glucose challenge (J Cardiovasc Pharmacol. 2012 
Feb;59(2):133-41) hence our observation here is not isolated. Naringin has not be 
demonstrated to be an insulin secretagogue and its proposed insulinotropic effects are 
apparent only in simulated type 2 diabetes models (Diabetes Res Clin Pract. 2012 
Jul;97(1):105-11). Currently available scientific evidence suggests that naringin and its 
aglycone naringenin could be acting like insulin sensitizers just like metformin (Arch 
Biochem Biophys. 2012 Feb 1;518(1):61-70; Biochem Biophys Res Commun. 2010 Jul 
23;398(2):178-83) by activating AMPK. In this context, it is not surprising that we did 
not observe improved glucose tolerance in a type 1 diabetes rat model. It cannot be 
argued that 3.0 g/kg body weight glucose used in this study was too high to show 
differences in IPGTT since even in non-STZ-treated rats, there were no significant 
difference in glucose tolerance between naringin-treated and control rats. A lower dose 
of glucose could have produced a flat curve considering the difference in blood glucose 
concentrations between STZ-treated and non-STZ-treated rats. 
With anticipated permission of the Editor, we have changed the title accordingly 
Main comments: 
 
1) The introduction and discussion are too long and particularly focused on ketoacidosis 
as the main source of all ailments in diabetes. Major revision is required to remove 
sensationalistic language, please use ONLY standard scientific language that 
describes facts and credit associated literature references. To be very specific, replace 
the words/sentences: “courtesy”, “exacerbate”, “catabolic nature”, “contentious 
issues”, “random blood glucose”, “diabetic state”; as well as convoluted/incorrect 
concepts like “pro-hyperglycemia insulin counter-regulatory hormones”, “freely 
producing hydrogen ions which bind an overwhelm serum bicarbonate buffering 
capacity eventually leading to metabolic acidosis”, “hyperglycemia-associated 
oxidative stress causes lipid peroxidation due to increased ROS leading to 
overproduction of MDA”. There are also a number of unsupported statements like 
“offer some hope”, “devoid of adverse effects”, “abrogated metabolic acidosis”, 
“metformin-like effects” and “demonstrated powerful antioxidant effect”. Note that 
“powerful” is not an objective and meaningful word in this context (i.e. low redox 
potential of the molecule? binds with high affinity to a target?). 
Response: 
Noted. The offensive words/phrases have been purged where appropriate and the 
introduction and discussion sections shortened. However, we need to point out that the 
study was designed primarily to investigate the effects of naringin on diabetic 
ketoacidosis with glucose intolerance as a confirmation of diabetes and oxidative stress 
as a possible mechanism of action. Diabetic ketoacidosis is not a source of diabetes but 
rather a metabolic complication besides nephropathy, cardiomyopathy, retinopathy and 
neuropathy which we were not intent on investigating in this setting.  
We see no problem with using some of the phrases such as “random blood glucose” 
which is clinically applicable as opposed to “fasting blood glucose”. Similarly we see 
nothing wrong with referring to naringin as having ‘metformin-like effects” in the 
control of blood glucose as it appears to be an emerging consensus among different 
investigators in this field. 
2) All instances of the sentence “Diabetic groups” (or “diabetic rats”) should be changed 
to “SZT-treated group”. Similarly, “untreated diabetic group” would be substituted 
with “SZT-treated control cohort”, etc. 
Response: 
Done 
3) Figure 1 shows the BW at the end of the study, please show a longitudinal scatterplot. 
Figure 4 shows only the fasting glucose on day 28 of treatment, however, day 0 and 
14 were also measured. This data should be included. 
Response: 
Done. 
4) Fasting plasma insulin (FPI) was measured on day 42, which is 1-day post GTT on day 41. 
Therefore, this protocol must have required 2 nights of fasting in a row with a short ad 
libitium feeding time in between, which is not a standard recovery post-GTT. This needs to 
be clarified and stated because it may possibly lead to differences with other study designs in 
the future. 
Response: 
Fasting blood glucose were done on days 0, 14 28 and 41 but not 42 as part of IPGTT. 
The error has been corrected. The animals were then sacrificed on day 42. 
4) The formulas for concentrations of [AcAc] and [3HB] are not consistent with 
concentration units. Please provide literature references for these methods. Please 
provide a reference for the quoted extinction coefficient of 1.56x10^5 for the MDA 
assay. Similarly, it would seem that the measurement of glycogen would require a 
standard curve to convert the spectrophotometer measurements to mg/g liver protein. 
Please include all data, literature references, and methods needed. 
Response: 
Anion Gap (AG) was calculated according to: Clin J Am Soc Nephrol. 2007 
Jan;2(1):162-74, (reference no 11 in the revised manuscript) and expressed as mM 
(mmol/L) which is also the same as mEq/L. References for MDA (S Afr J Sci 
2010;106:1-5) and glycogen determination (Arch Biochem 1950;25(1):191-200) are 
provided in the methods sections in the manuscript. Standard curves were used to 
determine the concentrations of the unknowns in all experiments and would not add 
value to the information on the figures unless provided as supplementary data. 
5) The single IPGTT experiment using a 3 g/kg dose of sugar is inconclusive because the 
resulting measurements ~30 mmol/L fall outside the “dynamic range” of blood 
glucose homeostasis. As observed in Figure 5B, these animals lacking beta-cells 
cannot effectively respond to such doses of sugar, and do not return to baseline even 
after 2.5 hr. Therefore, lack of differences in this experiment are insufficient evidence 
to support the negative claim. The manuscript should be modified to take into account 
this possibility. 
Response: 
Whatever the amount of glucose administered, blood glucose concentrations never 
return to baselines in GTT even after 2 hrs in diabetic individuals and this is one of the 
criteria clinically used to diagnose diabetes. Fasting blood glucose concentrations in 
STZ-treated rats were above 25 mM before loading glucose anyway, meaning that any 
amount of glucose loaded would have spiked blood glucose levels beyond physiological 
range. In non-STZ-treated rats, 3.0 g/kg did not increase blood glucose concentrations 
beyond physiological ranges and there were no differences between controls and 
naringin-treated groups even in the presence of insulin suggesting lack of hypoglycemic 
effects of naringin in normal or low insulin concentrations. A lower dose of glucose 
could have produced a flat curves considering the differences in blood glucose 
concentrations between STZ-treated and non-STZ-treated rats. Hypoglycemic effects of 
naringin are reported in simulated type 2 diabetes models where there is 
hyperinsulinemia (Nutrients. 2013 Feb 27;5(3):637-50). 
________________________________________ 
